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INTRODUCTION
Pneumonia  is  an  inflammation  of  the  lung  that  is  most  often  caused  by 
infection  with  bacteria,  viruses,  or  other  organisms.  Occasionally,  inhaled 
chemicals  that  irritate  the  lungs  can  cause  pneumonia.  Healthy  people  can 
usually  fight  off  pneumonia  infections.  However,  people  who  are  sick, 
including  those  who  are  recovering  from  the  flu  (influenza)  or  an  upper 
respiratory  illness,  have  weakened immune systems  that  make  it  easier  for 
bacteria to grow in their lungs.
 
When air is inhaled through the nose or mouth, it travels down the trachea to 
the bronchus, where it first enters the lung. From the bronchus, air goes through 
the bronchi, into the even smaller bronchioles and lastly into the alveoli 2.
DEFINING PNEUMONIA BY LOCATION IN THE LUNG
Pneumonia may be defined according to its location in the lung:
       • Lobar pneumonia occurs in one part, or lobe, of the lung.
 
       • Bronchopneumonia tends to be scattered throughout the lung. 
DEFINING PNEUMONIA BY ORIGIN OF INFECTION
COMMUNITY ACQUIRED PNEUMONIA (CAP). People with this type of 
pneumonia contracted the infection outside a hospital setting. It is one of the 
most common infectious diseases. It often follows a viral respiratory infection, 
such  as  the  flu.  Commonest  organism  causing  CAP  is  Streptococcus 
pneumoniae. Other pathogens include Haemophilus influenzae, Mycoplasma, 
and Chlamydia.
HOSPITAL  ACQUIRED  PNEUMONIA.(HAP)  Hospital-acquired 
pneumonia is an infection of the lungs contracted during a hospital stay. This 
type of pneumonia tends to be more serious, because hospital patients already 
have weakened defense mechanisms, and the infecting organisms are usually 
more dangerous than those encountered in the community. Hospital patients are 
particularly vulnerable to Gram-negative bacteria and staphylococci. Hospital-
acquired pneumonia is also called nosocomial pneumonia.
A  subgroup  of  hospital-acquired  pneumonia  is  Ventilator-Associated 
Pneumonia (VAP), a highly lethal form contracted by patients on ventilators in 
hospitals  and  long-term  nursing  facilities.  Ventilator  associated  pneumonia 
(VAP) is defined as nosocomial pneumonia occurring in a patient after 48 hours 
of mechanical ventilation via a tracheal or tracheostomy tube. It is commonly 
classified as either early onset (occurring within 96 hours of start of mechanical 
ventilation) or late onset (>96 hours after start of mechanical ventilation). It is a 
common condition, difficult to diagnose accurately, and expensive to treat. Its 
development prolongs a patient’s stay in the intensive care unit (ICU), and is 
associated with significant morbidity and mortality. Most cases seem to result 
from  aspiration  of  pathogenic  material  that  commonly  colonises  the 
oropharyngeal airways of  the critically  ill.  Simple measures to decrease the 
incidence of aspiration or reduce the burden of colonisation of the oropharynx 
may aid in the prevention of ventilator  associated pneumonia.  A favourable 
outcome seems to be more likely if appropriate antibiotics are given in a timely 
manner.42
EPIDEMIOLOGY
INCIDENCE
The  incidence  of  Ventilator  associated  pneumonia  (VAP)  was  7% to  70%. 
Generally, the rates of VAP in surgical ICU were higher than in medical ICUs, 
depending on the differences in the patient population, surgical disorders, the 
proportion of patients that needed MV and the duration of ventilation. The risk 
of pneumonia increased by the duration of MV and the highest risk was during 
the  first  8–10  days.  The  need  for  reintubation,  urgent  intubation  and 
documented massive aspiration are also associated with high incidence of VAP. 
In Korea, the incidence of VAP is 3.5 to 7.1 per 1000 ventilator days. In India 
overall rate of VAP of 8.95 per 1000 ventilator days 119
MORTALITY 
VAP is associated with increases in morbidity and mortality, hospital length of 
stay, and costs. The mortality rate attributable to VAP is 27% and has been as 
high  as  43% especially  when  antibiotic  resistant  bacteria  were  responsible. 
Length of stay in the intensive care unit is increased by 5 to 7 days and hospital 
length of stay 2- to 3-fold in patients with VAP. Mortality is more likely when 
VAP is associated with certain microorganisms (Pseudomonas, Acinetobacter), 
blood stream infections, and ineffective initial antibiotics.  VAP is especially 
common in people who have acute respiratory distress syndrome (ARDS). In 
the  Philippines,  the  crude  mortality  rate  for  hospitalized  patients  with 
pneumonia was 42.4%, with a mortality rate attributable to infection of 30.1%. 
India on HAP that found an overall crude mortality of 67.4% in ICU patients 
with pneumonia,  with 40% of the  mortality  in these  patients  attributable  to 
infection alone 119.
Risk factors for ventilator-associated pneumonia 
 Duration of mechanical ventilation
 Aspiration of gastric contents 
 Chronic obstructive pulmonary disease
 Histamine type-2 receptor antagonist
 Nasal intubation and/or sinusitis
 Use of positive end-expiratory pressure
 Reintubation
 Intracranial pressure monitoring and/or depressed consciousness
 Winter season
 Daily ventilator circuit changes
 Thoracic or upper abdominal surgery
 Age
 Multiple organ system failure
 Prior antibiotic administration
 Supine head positioning (i.e., head of bed not elevated)
 Duration of hospitalization prior to mechanical ventilation
PATHOPHYSIOLOGY
Ventilator  associated  pneumonia  (VAP)  primarily  occurs  because  the 
endotracheal  or  tracheostomy  tube  allows  free  passage  of  bacteria  into  the 
lower  segments  of  the  lung  in  a  person who often  has  underlying  lung or 
immune  problems.  Bacteria  travel  in  small  droplets  both  through  the 
endotracheal  tube  and  around  the  cuff.  Often,  bacteria  colonize  the 
endotracheal or tracheostomy tube and are embolized into the lungs with each 
breath. Bacteria may also be brought down into the lungs with procedures such 
as deep suctioning or bronchoscopy.
Whether bacteria also travel from the sinuses or the stomach into the lungs is, 
as of 2005, controversial. However, spread to the lungs from the blood stream 
or the gut is uncommon.
Once inside the lungs, bacteria then take advantage of any deficiencies in the 
immune system (such as due to malnutrition or chemotherapy) and multiply. A 
combination of bacterial  damage and consequences of the immune response 
lead to disruption of gas exchange with resulting symptoms. 91
Pathogenic mechanisms for infection of the lower 
Respiratory tract 
MICROBIOLOGY
The microbiologic flora responsible for Ventilator associated pneumonia (VAP) 
is  different  from that  of  the more common community-acquired pneumonia 
(CAP). In particular, viruses and fungi are uncommon causes in people who do 
not  have  underlying  immune  deficiencies.  Though  any  microorganism  that 
causes CAP can cause VAP, there are several bacteria which are particularly 
important  causes  of  VAP  because  of  their  resistance  to  commonly  used 
antibiotics. These bacteria are referred to as multidrug resistant 
(MDR).
• Pseudomonas  aeruginosa  is  the  most  common  MDR  Gram-negative 
bacterium causing VAP.  Pseudomonas has  natural  resistance to  many 
antibiotics and has been known to acquire resistance to every antibiotic 
except  for  polymixin  B.  Resistance  is  typically  acquired  through  up 
regulation  or  mutation  of  a  variety  of  efflux  pumps  which  pump 
antibiotics out of the cell. Resistance may also occur through loss of an 
outer membrane porin channel (OprD) 
• Klebsiella  pneumoniae  has  natural  resistance  to  some  beta-lactam 
antibiotics  such  as  Ampicillin.  Resistance  to  cephalosporins  and 
aztreonam may  arise  through  induction  of  a  plasmid-based  extended 
spectrum beta-lactamase (ESBL) or plasmid-based ampC-type enzyme. 
Enterobacter, Citrobacter and also Serratia marcescens as a group also 
have an inducible ampC gene,  which can be induced by exposure to 
antibiotics  such  as  cephalosporins.  Thus,  culture  sensitivities  may 
initially  indicate  appropriate  treatment  which  fails  due  to  bacterial 
response. They may also develop resistance by acquiring plasmids. 
• Stenotrophomonas maltophilia and Acinetobacter often colonizes people 
who  have  endotracheal  tubes  or  tracheostomies  but  can  also  cause 
pneumonia. They are often resistant to a wide array of antibiotics but are 
usually sensitive to co-trimoxazole. 
• Burkholderia  cepacia  is  an  important  organism in  people  with  cystic 
fibrosis is often resistant to multiple antibiotics. 
• Methicillin-resistant  Staphylococcus  aureus  is  an  increasing  cause  of 
VAP. As many as fifty percent of Staphylococcus aureus isolates in the 
intensive care setting are resistant to methicillin. Resistance is conferred 
by the mecA gene. 106        
Nosocomial virus and fungal infections are uncommon causes of HAP and VAP 
in immunocompetent patients. Fungal pathogens causing VAP are Aspergillus 
species and Candida albicans.
DIAGNOSIS
The diagnosis of pneumonia in mechanically ventilated patients is difficult, and 
still there is no "gold-standard" diagnostic method. It is usually based on the 
combination of clinical,  radiological, and microbiological criteria defined by 
Centers for Disease and Control (CDC) 
CDC criteria for ventilator associated pneumonia
 
Three or more of the following criteria:
 
• Rectal temperature >38°C or <35.5°C
 
• Blood  leucocytosis  (>10.103/mm3)  and/or  left  shift  or  blood 
leukopenia (<3.103/mm3)
 
• More than ten leukocytes in Gram stain of tracheal aspirate (in high 
power field)
 
• Positive culture from endotracheal aspirate
 
       
• New, persistent, or progressive radiographical infiltrate
But these criteria have low sensitivity and specificity. The systemic signs fever, 
leukocytosis, etc.)  of infection can be seen by any condition in ICU pulmonary 
edema, pulmonary infarction, after surgery, trauma, devascularized tissue, open 
wounds,  etc.).  Investigators  reported  that  the  clinical  diagnosis  of  VAP is 
associated with 30–35% false-negative and 20–25% false-positive Results. And 
also, ICU patients do not always have systemic signs of infection due to their 
underlying  disease  (chronic  renal  failure,  immunosuppression,  etc.). 
Radiological  infiltration  has  limited  value,  mimicking  by  cardiogenic 
pulmonary edema, noncardiogenic pulmonary edema, adult respiratory distress 
Syndrome(ARDS), atelectasis, pulmonary contusion, which are not uncommon 
in ICU. 
The upper respiratory tract of patients is colonized with potential pulmonary 
pathogens a few hours after intubation .Consequently, isolation of pathogens 
from tracheal  secretions  do  not  always indicate  pulmonary  infection.  But  a 
positive Gram's stain may guide the initial antibiotic therapy. However prior 
antibiotic and corticosteroid therapy can reduce the sensitivity of this technique 
CLINICAL PULMONARY INFECTION SCORE (CPIS)
This  score  combine  the  seven  variables  (temperature,  leukocytes,  tracheal 
aspirate volume and purulence of tracheal secretions, chest X-ray, oxygenation-
PaO2/FiO2- and semi quantitative culture of tracheal aspirate) for the diagnosis 
of VAP, defined as clinical pulmonary infection score (CPIS) 
Clinical pulmonary infection score
Temperature, °C ≥ 36.5 and ≤ 38.4 0 point
≥ 38.5 and ≤ 38.9 1 point
≥ 39.0 and ≤ 36.0 2 point
Blood leucocytosis, mm3 ≥ 4000 and ≤ 11 000 0 point
<4000 and >11 000 1 point
     +band forms ≥ 500 + 1 point
Tracheal secretions <14+ of tracheal secretions 0 point
≥ 14+secretions 1 point
     +purulent sputum +1 point
Oxygenation: PaO2/FiO2, mmHg >240 or ARDS 0 point
≤ 240 and no ARDS 2 point
Chest X-ray No infiltrate 0 point
Diffused, or patchy infiltrate 1 point
Localized infiltrate 2 point
Culture of tracheal aspirate (semi-quantitative: 0-
1-2 or 3+) ≤ 1 or no growth 0 points
     Pathogenic bacteria cultured >1+ 1 point
>1+  and same pathogenic  bacteria  seen in 
Gram stain 2 point
The score varied from 0 to 12 points and was reported that a CPIS of more than 
six was associated with a sensitivity of 93% and a specificity of 100% for the 
diagnosis  of  pneumonia.  However,  the  original  scoring  system  has  some 
limitations;  that  it  requires  24–48  hours  for  the  results  of  tracheal  aspirate 
cultures,  and  also  identifying  pulmonary  infiltrates  progression  depends  on 
intensivist experience. Modified CPIS (calculated at baseline from the first five 
clinical variables, and CPIS at 72 hours was based on all variables of the score) 
that antibiotics were stopped in patients with a persistent low score (<6) after 3 
days of therapy, avoiding unnecessary use of antibiotics, and all patients who 
discontinued the therapy improved. The modified CPIS does not perform better 
when  the  clinical  suspicion  of  pneumonia  is  high,  so  they  proposed 
incorporating the results of specimens gram stain (by adding two more points 
when gram stains were positive) to modified CPIS to increase the sensitivity of 
the score and the physicians' diagnostic accuracy.
Qualitative  cultures  of  tracheal  aspirate  (TA)  is  not  a  specific  diagnostic 
method  because  of  the  lower  respiratory  tract  colonization  and  a  high 
percentage  of  false-positive  results  .However,  investigators  reported  that 
quantitative cultures of TA have equal diagnostic accuracy to the other invasive 
techniques . Although, quantitative cultures of TA is non-invasive, inexpensive 
and a simple method, it has some risks, that if the cut-off value ≥ 106 cfu/mL is 
used, sensitivity will be low and some patients with VAP may not be identified 
or when the cut-off value ≥ 105 cfu/mL is used, unnecessary antibiotic treatment 
will be given because of low specificity. 96
INVASIVE TECHNIQUES FOR THE DIAGNOSIS OF VAP
1. Protected-specimen brush (PSB)
2. Bronchoalveolar lavage     (BAL)
3. Blood or pleural fluid
In PSB, 0.001 mL of secretions are collected and the presence of >103 cfu/mL 
bacteria have 80–90% sensitivity and 95% specificity for the diagnosis of VAP. 
In BAL, larger proportion of lung can be sampled and the diagnostic threshold 
is >104 cfu/ml. The sensitivity and specificity of BAL are 86–100% and 95– 
100%, respectively .102 
The disadvantages of these invasive techniques are; 
a) Prior antibiotic use may decrease the sensitivity and accuracy of these 
methods. 
b) These techniques are based on quantitative culture and results of these 
cultures require 24–48 hours, and, therefore miss early cases, and also 
give no information about appropriate initial antibiotic therapy.
c) These  invasive  tests  may  worsen  the  patient's  status  (cardiac 
arrhythmias,      hypoxemia, bleeding, etc.). 
d) Increase the costs of caring. 
e) It has not been proven that the use of these invasive   techniques lead to 
a decrease in patients' mortality.
The spread of microorganism to blood or pleural space is <10%, so blood and 
pleural effusion cultures have low sensitivity and specificity. Blood cultures in 
patients with VAP are useful if there is suspicion of another probable infectious 
condition, but the isolation of a microorganism in the blood does not confirm 
that microorganism as the pathogen causing Ventilator Associated Pneumonia. 
Therefore, two sets of blood samples for culture and tapping pleural effusions 
>10  mm  should  be  performed  in  patients  suspected  Ventilator  Associated 
Pneumonia.
Microbiological testing should be always performed to decide the appropriate 
initial  empirical  antibiotic therapy. Clinicians can choose optimal diagnostic 
test for specific patients in their clinical setting.98
MANAGEMENT OF VENTILATOR ASSOCIATED PNEUMONIA
Early  recognition  and  appropriate  management  of  ventilator-Associated 
Pneumonia reduces the incidence of complications such as acute lung injury, 
multiple organ dysfunction and respiratory decompensation. Empirical therapy 
should be started as a matter of urgency if infection is identified.  Unnecessary 
delay in antibiotic therapy leads to adverse outcomes, particularly if the patient 
is  septic  .However,  antibiotic  therapy  for  non-infective  syndromes  is  also 
detrimental.  It is important to balance the risks and benefits of treatment and 
this is a matter for individual clinical judgement. 
Antibiotic rationale
Empirical therapy will usually take into account:
• Time of onset of illness (<5 vs. 5 days after admission) and therefore  
probable pathogens 
• Previous antibiotic administration  (rates of Pseudomonas  aeruginosa or 
Acinetobacter  spp.  infection  increase  significantly  in  patients  treated 
with antibiotics within 10 days before the onset of pneumonia) 
• Severity and speed of progression of the illness 
• Local pathogens and resistance patterns      
• Other patient-related factors such as renal or hepatic impairment. 
Therapy should be broad-spectrum, and have high activity against the probable 
pathogens.  In  patients  previously untreated with antibiotics the  predominant 
pathogens  are  Gram-positive  cocci  in  ‘early’ infections  and  aerobic  Gram-
negative  bacilli  in  ‘late’ infections.  There  are  some  data  to  suggest  that 
monotherapy may be as effective as combination therapy in severe ventilator- 
associated pneumonia.130 
However, there is considerable debate about the merits of monotherapy in these 
patients largely because of some limitations in the data, particularly the range 
of infections included in the trials, the sample sizes and the use of sub-optimal 
doses of Aminoglycosides. Combination therapy has the advantage of giving 
cover against a broader-spectrum of organisms and some combinations have a 
synergistic  mechanism of  action  which  reduces  the  potential  for  resistance 
developing  during  treatment,  e.g.  an  Aminoglycosides  with  a  beta-lactam. 
Pseudomonas aeruginosa has been associated with resistance developing during 
the course of treatment and therefore if pseudomonas involvement is suspected, 
vigorous anti-pseudomonas therapy is indicated.35 
Empirical therapy
Given that there is minimal margin for error in seriously ill patients, it would be 
prudent  to  use  empirical  combination  therapy.   Factors  to  be  considered 
include:
      • Previous antibiotic therapy 
      • Known prevalence and resistance patterns 
      • Patient condition. 
If a satisfactory clinical response is observed with combination therapy after –4 
days, monotherapy can be considered and the Aminoglycosides withdrawn. The 
optimal  treatment  duration  has  not  been established  in  ventilator-associated 
pneumonia.  Most  studies  report  treatment  durations  of  7–10 days,  although 
shorter courses may be effective.26
PREVENTION OF VENTILATOR ASSOCIATED PNEUMONIA
The following measures to reduce Ventilator Associated Pneumonia:
• Strict infection control policies
 Alcohol-based hand disinfection
 Collection  of  timely  microbiologic  surveillance  data  on 
multidrug- resistant pathogens
 Monitoring and early removal of invasive devices
 Programs to reduce antibiotic prescribing practices
 Continuous aspiration of subglottic secretions
 Detection of pneumonia and deescalation of drug treatment
• Use of oral rather than nasal endotracheal tubes
• Maintenance of endotracheal cuff pressure > 20 cm H20
• Limited use of sedative and paralytic agents
• Positioning of the patient
  Semi recumbent positioning (30 to 45 degrees) is recommended 
to reduce the risk of aspiration.
 Proper care should be taken when turning the patient or the bed 
rail is raised to avoid inadvertently flushing the condensate that 
collects on the ventilator circuit into the lower airway or to inline 
medication nebulizers.
• Intensive insulin therapy to maintain normal blood glucose level
• Emphasis on bleeding prophylaxis; use of H2 antagonists or sucralfate
• Avoidance  of  intubation  by  using  noninvasive  ventilation  wherever 
possible,  particularly  in  patients  with  chronic  obstructive  pulmonary 
disease and cardiogenic pulmonary edema
• Avoidance of blood transfusion
• Adequate nurse-to-patient ratios
• Staff education 40
Though various Indian and International studies on epidemiology of Ventilator 
Associated Pneumonia  are  available,  no such study has been carried out in 
Madurai.  Since  Government  Rajaji  Hospital,  (GRH)  Madurai  is  the  largest 
tertiary care hospital attached to Madurai Medical College catering to the needs 
of lakhs of people from southern districts of Tamilnadu, the present study was 
carried  out  among  patients  admitted  at  Intensive  Respiratory  Care  Unit, 
Government  Rajaji  Hospital  in  Ventilators  and the  data  were  analysed with 
reference to objectives.
   
Efforts  have  been  made  to  diagnose  ventilator  associated  pneumonia  by 
collecting   blood,  bronchoscopic  and  non  bronchoscopic  sampling,  from 
patients  satisfying  CDC  criteria  of  Ventilator  Associated  Pneumonia  and 
processing  them  by  various   microbiological  techniques  like  Gram  stain, 
isolation  of  microbes  using  quantitative  culture  methods  and  antimicrobial 
susceptibility  testing..  In  addition,  fungal  culture  was  also  performed.  The 
results were analysed sample wise and also technique wise and epidemiological 
factors of Ventilator Associated Pneumonia were studied. 
AIM AND OBJECTIVES OF THE STUDY
The  study  on  microbial  etiology  of
 
Ventilator
 
Associated  Pneumonia  was 
conducted  on  patients  admitted  into  the  Respiratory  Intensive  Care  Unit  of 
Government  Rajaji  Hospital  and  was  put  on  mechanical  Ventilation.  The 
objectives of the study were
1. To understand the prevalence of various pathogens causing Ventilator 
Associated Pneumonias.
2. To assess the usefulness of clinical samples obtained from patients with 
suspected Ventilator Associated Pneumonias in the diagnosis.
3. To find  if  clinically  relevant  correlations  exist  between age,  sex  and 
underlying clinical conditions.
4. Having identified pathogens, antibiotic susceptibility patterns would be 
studied.
5. To  understand  prognosis  of  patients  with  Ventilator  Associated 
Pneumonias.
6. To  be  able  to  develop  strategies  that  would  bring  down  Ventilator 
Associated Pneumonia in patients on mechanical ventilation.
REVIEW OF LITERATURE
DEFINITION
Johanson  WG  Jr,  Pierce  AK,  Sanford  JP,  Thomas  GD  et  al86 defined 
ventilator  associated  pneumonia  as  nosocomial  pneumonia  in  a  patient  on 
mechanical ventilatory support by endotracheal tube or tracheotomy for more 
than  48  hours.  For  many  years  ventilator  associated  pneumonia  has  been 
diagnosed by the  clinical criteria published by the  Johansson et al87 in 1972 
which  include  the  appearance  of  new or  progressive  pulmonary  in  filtrate, 
fever, leukocytosis, and purulent tracheobronchial secretion.(1972).
Kollef MH et al92 showed the onset of ventilator associated pneumonia into 2 
types; early and late.  Early onset ventilator associated pneumonia occurs 48 
hours to 96 hours after intubation and is associated with antibiotic susceptible 
organisms.  Late onset  ventilator associated pneumonia occurs more than 96 
hours  after  intubation  and  is  associated  with  antibiotic  resistant  organisms. 
Interventions to prevent ventilator associated pneumonia should begin at the 
time of or if possible, before intubation. (1995).
PREVALENCE AND GEOGRAPHICAL DISTRIBUTION
Bowton DL et al30 showed in their study that  the incidence of nosocomial 
pneumonia in mechanically  ventilated patients  ranges from 9% to 68% and 
mortality rates ranges from 33% to 71%. (2006).
Thongpiyapoom S, Narong MN, Petdachai W. et al144 in their article stated 
that incidence of VAP varying from 3.5 to 46 per 1000 ventilator days. A recent 
study from Thailand found incidences of VAP of 10.8 per 1000ventilator days 
in an adult ICU and 70.3 per 1000 ventilator days in newborn patients.  An 
Indian study of 51 critical care unit patients found an incidence of VAP of 46
per 1000 ventilator days (33% early onset and 67% late onset). From Hong 
Kong,  surveillance  data  collected  in  2004–2005  from  a  large  tertiary  care 
hospital represented in the panel found an incidence of VAP of 10.6 per 1000 
ventilator days. (2004)
Rakshit P, Nagar VS, Deshpande AK et al120 mentioned that VAP accounts 
for 2.9% of all nosocomial infections. One Chinese study reported that 41.2% 
of intubated patients developed VAP, with an incidence of 1 per 1000 ventilator 
days. (2005)
Thanamee  N,  Sujaritjan  N,  Techasena  W139in  their  study  observed  that 
pneumonia on mechanical ventilation in the ICU found a overall rate of 7.5% 
(17.5% in  the  paediatric  ICU,  6.5% in  the  medical  ICU,  and  2.5% in  the 
surgical ICU). In a recent Indian study of 328 patients in the ICU, the overall 
rate of HAP was reported to be 53.9%, and that of VAP was 81.7%. (1995)
Saenghirunvattana  S,  Charoenpan P,  Kiatboonsri  S,  Aeursudkij  B137 in 
their article described that the mortality for HAP (including VAP) ranged from 
25% to  54%.  In  China,  several  epidemiologic  studies  have  been published 
recently,  but  the  data  are  generally  of  poor  quality.  One  limitation  to  such 
studies is that much data are drawn from major metropolitan medical centres, 
such  as  Shanghai  and  Beijing,  with  little  date  from  the  relatively  under 
developed areas of China. A Chinese study of 372 patients with HAP found an 
overall mortality rate of 25.3%. Mortality rates associated with Pseudomonas 
spp  and  Staphylococcus  aureus  infection  were  higher,  70.6%  and  66.7%, 
respectively.(1994)
Zhang  Y150 in  his  article  reported  that  a  mortality  rate  was  47%  in 
immunocompetent  patients  who  acquired  nosocomial  pneumonia,  compared 
with  54% for  immunocompromised  patients.  A Taiwanese  study  conducted 
over  a  5-year  period  reported  overall  mortality  of  42.6%  in  patients  with 
respiratory tract infections and 61.5% for patients in the surgical ICU. These 
findings are comparable to those from a study in India on HAP that found an 
over all crude mortality of 67.4% in ICU patients with pneumonia, with 40% of 
the mortality in these patients attributable to infection alone. In the Philippines, 
the crude mortality rate for hospitalized patients with pneumonia was 42.4%, 
with a mortality rate attributable to infection of 30.1%. In the Philippines, local 
data presented by the panel demonstrated a mortality rate of 42% for HAP. 
Very little data are available on mortality associated specifically with VAP. A 
prospective study in Singapore reported a mortality rate of 73% for VAP. A 
Chinese study of 120 patients with VAP reported a 14% mortality rate directly 
related to this  infection.23 A Thai study of mechanically  ventilated patients 
reported  that  22.5%  (9/40)  of  patients  died  of  VAP.  A study  from  India 
evaluated 51 patients in the critical care unit and found a mortality rate of 37% 
attributable to VAP, which also correlated very well with higher APACHE III 
scores;  33%  of  the  cases  were  early  onset,  and  67%  were  late  onset.  In 
Thailand, a study of newborn ICU patients on a ventilator found a mortality 
rate of 29.4% in infants with VAP versus 30.6% in newborn infants in the ICU 
without VAP. (1991)
PAHOGENESIS
Livingston DH et al98 showed the pathophysiology of  ventilator  associated 
pneumonia  involves  2  main  processes.  Colonization  of  respiratory  and 
digestive tracts and micro aspiration of secretions of the upper and lower parts 
of the airway. (2000)
Bonten   MJM,  Gaillard  CA,  de  Leeuw  PW,  Stobberingh  EE  et  al29 
demonstrated  nosocomial  pneumonia  is  often  endogenous  in  origin,  the 
contribution of  exogenous microorganisms from other  sites,  may have been 
under  estimated,  infection  can  arise  from  microorganisms  in  the  ventilator 
circuit.  It  has  been  breakdown  of  a  single  step  in  the  procedure  for 
decontaminating  ventilation  equipment  can  be  responsible  for  infectious 
episodes. (1995)
Johhanson et al87 established that there is a link between the colonization of 
the patients airways, and the development of nosocomial pneumonia, and also 
he showed that the colonization of airway is connected to the contamination of 
the breathing circuit. (1988).
Kunis KA, Puntillo KA et al93 studied the colonization of bacteria refers to the 
presence of bacteria without an active host response. Bacterial colonization of 
the  lungs  can  be  due  to  spread of  organisms from many  different  sources, 
including the oropharynx, sinus cavities, nares, dental plaques, gastrointestinal 
tract, patient to patient contact and ventilation circuit. Inhalation of colonized 
bacteria  from  any  of  these  sources  can  cause  an  active  host  response  and 
ultimately ventilator associated pneumonia. (2003)
Olson  ME,  Harmon  BG,  Kollef  MH,  More  head  RS,  Pinto  SJ  et  al108 
demonstrated the presence of an endotracheal tube provides a direct route for 
colonized bacteria to enter the lower respiratory tract, upper air way and oral 
secretions can pool above the cuff of an endotracheal tube and line the tube, 
forming a biofilm. Starting as early as 12 hours after intubation, the biofilm 
contains large amount of bacteria that can be disseminated into the lungs by 
ventilator induced breaths. (2002)
De Rosa FG, Craven DE et al57 showed that the upper air way is by passed, a 
decreased occurrence in the body’s ability to filter and humidify air, in addition, 
the cough reflex is often eliminated and or decreased by the presence of an 
endotracheal  tube  and  mucociliary  clearance  can  be  improved  because  of 
mucosal injury during intubation. An endotracheal tube provides a place for 
bacteria to bind in the trachea, a situation that further increases production of 
secretion of mucus. The impairment of these natural host defense mechanisms 
increases the likelihood of bacterial colonization and subsequent aspiration of 
the colonized organisms. (2003).
Cook D, De Jonghe B, Brochard L, Brun- Bruisson C et al47 studied the 
pathogenesis of ventilator associated pneumonia is related to host and treatment 
related  colonization  factors.  Aspiration  of  oropharyngeal  pathogens  and the 
leakage of secretions containing bacteria around the endotracheal tube are the 
principal factors for the development of ventilator associated pneumonia. The 
progression  from  colonization  to  tracheobronchitis  to  ventilator  associated 
pneumonia is a dynamic equilibrium. (1998)
Ferror R, Artigas A et al70 showed that aspiration of gastric contents is another 
potential cause of ventilator associated pneumonia, because the stomach serves 
as a reservoir for bacteria, most patients receiving mechanical ventilation have 
a  naso  gastric  or  an  orogastric   tube  in  place  for  Enteral  feeding  and  a 
administration  of  medication or  for  gastric  decompression.  The presence of 
nasogastric  or  an orogastric  tube  interrupts  the  gastro  esophageal  sphincter, 
leading to increased gastrointestinal reflux and providing a route for bacteria to 
translocate to the oropharynx and colonize the upper airway. Enteral feedings 
increase  both  gastric  ph  and  gastric  volume,  increasing  the  risk  of  both 
bacterial colonization and aspiration. (2001).
RISK FACTORS
Torres A, de la Bellacasa JP, Rodriguez RR, Jimenez M, Agusti VA et al143 
studied the risk factors for ventilator associated pneumonia can be divided into 
3 categories; host related, device related and personnel related. Host related 
risk factors include preexisting conditions such as immunosuppression, chronic 
obstructive pulmonary disease and acute respiratory distress syndrome. Others 
include  patient’s  body  positioning,  level  of  consciousness,  number  of 
intubation and medications, including sedative agents and antibiotics. In one 
study, bacterial contamination of endotracheal secretions was higher in patients 
in the supine position than in patients in semi recumbent position. Whether due 
to  a  pathophysiological  process,  medication  in  injury,  decreased  level  of 
consciousness resulting in the loss of cough and gag reflexes contributes to the 
risk  of  aspiration  and  therefore  increases  the  risk  for  ventilator  associated 
pneumonia.  Re-intubation  and  subsequent  aspiration  can  increases  the 
likelihood of ventilator associated pneumonia 6 fold. (1988)
Kollef  MH et al92 studied   Improper hand washing resulting in the cross-
contamination of patients is the biggest personnel-related risk factor for VAP. 
Patients  who are  intubated  and receiving  mechanical  ventilation often  need 
interventions such as suctioning or manipulation of the ventilator circuit. These 
interventions increase the likelihood of cross-contamination between patients if 
healthcare staffs do not use proper hand-washing techniques. Failure to wash 
hands and change gloves between contaminated  patients has  been associated 
with  an  increased  incidence  of   VAP  In  addition,  failure  to  wear  proper 
personal protect-resistant organisms  have been identified increases the risk of 
cross-contamination between  patients. (1995) 
Bergmans DC, Bonten MJ, Gaillard CA,  et al26 demonstrated retention of 
liquid borne contamination is particularly important in mechanical ventilation. 
Potentially contaminated patient fluids, such as tracheal secretions, saliva and 
blood  can  be  present  in  the  expired  air  and  can  provide  a  source  of 
contamination into the breathing system. Hygroscopic devices are unable to 
provide against ventilator associated pneumonia. (2001)
Lorente L, Lecuona M, Jimenez A, Mora ML, Sierra A et al97 suggests that 
using heat and moisture exchangers instead of heated humidifiers, may increase 
the incidence of ventilator associated pneumonia. (2006)
Niederman MS, Ferranti RD, Zeigler A, Merrill WW, Reynolds HY et al106 
showed Risk factors for tracheobronchial colonization with GNB appear to be 
the same as those that favor pneumonia and include more severe illness, longer 
hospitalization, prior or concomitant use of antibiotics, malnutrition, intubation, 
azotemia, and underlying pulmonary disease. Experimental investigations have 
linked some of these risk factors to changes in adherence of GNB to respiratory 
epithelial  cells.  Although  formerly  attributed  to  losses  of  cell  surface 
fibronectin, these changes in adherence more likely reflect alterations of cell 
surface  carbohydrates.  Bacterial  adhesins  and  prior  antimicrobial  therapy 
appear to facilitate the process. Interestingly, Enterobacteriaceae usually appear 
in the oropharynx first, whereas P. aeruginosa more often appears first in the 
trachea (1994)
ETIOLOGICAL AGENTS
Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C Pugin 
J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter P et al69  showed 
Bacterial agents causing nosocomial pneumonia in patients from ATS Group 1 
are  defined  as  "core  organisms"  and  include:  enteric  Gram-negative  bacilli 
(Enterobacter  sps,  Escherichia  coli,  Klebsiella  sps,  Proteus  sps,  Serratia 
marcescens),  Haemophilus  influenzae,  Streptococcus  pneumoniae  and 
methicillin sensitive Staphylococcus aureus. Organisms related to ATS Group 2 
pneumonia  include  those  of  ATS Group  1  but  also  anaerobes,  Leigeonella 
pneumophilia,  methicillin  resistant  S.  aureus  (MRSA) and P.  aeruginosa.  In 
ATS Group 3 pneumonia, "core organisms" are often isolated but additional 
pathogens like  P.  aeruginosa,  Acinetobacter  spp.  and methicillin  resistant  S. 
aureus are also frequent. Patients belonging to this category are at risk of being 
infected with potentially multiresistant organisms. In mechanically ventilated 
patients, VAP is polymicrobial in 40% of cases. (2000).
Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C, Gibert C 
et al68 studied gram negative bacteria are the most common pathogens cause 
ventilator associated pneumonia.(1993)
Richards  MJ , Edwards JR,Culver DH, Gaynes RP et al118 studied the most 
common  gram  negative  species  were   pseudomonas  aeruginosa  (15.6%), 
Enterobacter species (10.9%), and Klebsiella pneumoniae (7%). (1999) 
Chastre  J,Trouillet JL, Vuagnat A, Joiy-Guillou ML, Clavier H, Dombret 
MC, Gibert C et al51 studied polymicrobial infection rate is usually high in 
ventilator associated pneumonia. (1989).
Gayness R, Edwards JR et  al75 showed data from the US based National 
Nosocomial  Infections  Surveillance  (NNIS)  System  from  2003  found  that 
Staphylococcus aureus (27.8%) was the most common pathogen  associated 
with  ventilator associated pneumonia, followed by pseudomonas aeruginosa 
(18.1%),  Enterobacter  species  (10%),  Klebsiella  pneumoniae  (7.2%),  and 
Acinetobacter species (6.9%). (2005).
Kollef  MH, Shorr A,  Tabak YP,  Gupta V, Lui  LZ,  Johannes RS et  al91 
showed another recent US multicentre survey found staphylococcus aureus and 
pseudomonas  aeruginosa   to  be  the  most  common  causes  of  nosocomial 
pneumonia. (2005).      
Jiménez P et al90 studied Antibiotic resistant microorganisms are commonly 
found  in  VAP.   Staphylococcus  aureus,  Pseudomonas  aeruginosa,  and 
Haemophilus  influenzae  were  the  most  common  causes  of  nosocomial 
pneumonia in the late 1990s. The presence of methicillin-resistant strains of S. 
aureus,  vancomycin-resistant  Enterobacter  species,  and  b-lactam-resistant 
streptococci  also  increased  significantly  during  this  period  and  are  now 
commonly  associated with VAP.  The presence of  resistant  P.  aeruginosa is 
significantly  associated  with  mortality.   Antibiotic  resistance  and  improper 
antimicrobial therapy contribute to mortality in patients with VAP. (1989).
Antonelli M, Moro ML, Capelli O, De Blasi RA, D'Errico RR, Conti 
G,  Bufi  M,  Gasparetto  A et  al8 studied  The  prognosis  for  aerobic,  gram-
negative bacilli (GNB) VAP is considerably worse than that for infection with 
gram-positive  pathogens,  when  these  organisms  are  fully  susceptible  to 
antibiotics.  Death  rates  associated  with  Pseudomonas  pneumonia  are 
particularly  high,  ranging  from  70  to  more  than  80%  in  several  studies. 
According  to  one  study,  mortality  associated  with  Pseudomonas  or 
Acinetobacter pneumonia was 87% compared with 55% for pneumonias due to 
other organisms.  Similarly,  Kollef and coworkers demonstrated that  patients 
with VAP due to high-risk pathogens (Pseudomonas aeruginosa, Acinetobacter 
spp.,  and Stenotrophomonas maltophilia)  had a significantly  higher  hospital 
mortality rate (65%) than patients with late-onset VAP due to other microbes 
(31%) or patients without late-onset pneumonia (37%) (65). Concerning gram-
positive  pathogens,  in  a  study  comparing  VAP due  to  methicillin-resistant 
Staphylococcus  aureus  (MRSA)  or  methicillin-sensitive  S.  aureus  (MSSA), 
mortality was found to be directly attributable to pneumonia for 86% of the 
former cases versus 12% of the latter, with a relative risk of death equal to 20.7 
for MRSA pneumonia (1998). 
el-Ebiary  M,  Torres  A,  Fabregas  N,  de  la  Bellacasa  JP,  Gonzalez  J, 
Ramirez J, del Bano D, Hernandez C, Jimenez de Anta MT et al64 studied 
Isolation  of  fungi,  most  frequently  Candida  species,  at  significant 
concentrations  poses  interpretative  problems.  Invasive  disease  has  been 
reported in VAP but, more frequently, yeasts are isolated from respiratory tract 
specimens in the apparent absence of disease. One prospective study examined 
the relevance of isolating Candida spp. from 25 non-neutropenic patients who 
had been mechanically ventilated for at least 72 hours. Just after death, multiple 
culture  and  biopsy  specimens  were  obtained  by  bronchoscopic  techniques. 
Although 10 patients had at least one biopsy specimen positive for Candida 
spp.,  only  two  had  evidence  of  invasive  pneumonia  as  demonstrated  by 
histological examination. Many of the endotracheal aspirates, PSB specimens, 
and BAL specimens also yielded positive cultures for Candida spp., sometimes 
in  high  concentrations,  but  they  did  not  contribute  to  diagnosing  invasive 
disease.  On  the  basis  of  these  data,  the  use  of  the  commonly  available 
respiratory  sampling  methods  (bronchoscopic  or  nonbronchoscopic)  in 
mechanically  ventilated  patients  appears  insufficient  for  the  diagnosis  of 
Candida pneumonia. At present, the only sure method to establish that Candida 
is the primary lung pathogen is to demonstrate yeast or pseudohyphae in a lung 
biopsy.  However,  the  significance of  Candida isolation  from the respiratory 
samples of mechanically ventilated patients merits being investigated in greater 
depth (1993). 
DIAGNOSTIC STRATEGIES
Clinical Strategy
Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM et al113 
showed body temperature, white blood cell count, volume and appearance of 
tracheal secretion, oxygenation (PAo2/Fio2), chest X ray and tracheal aspirate 
cultures  into  a  clinical  pulmonary  infection  score  as  a  diagnostic  tool  for 
pneumonia. They found that clinical pulmonary infection score of more than 
six was associated with sensitivity 93% and a specificity of 100%. (1991)
Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL et al136 used modified 
clinical pulmonary infection score with in a clinical management algorithm in 
an attempt to reduce unnecessary antibiotic use in patients in whom ventilator 
associated pneumonia was suspected. In this series of patients, modified score 
remaining less than six at 3 days safely allowed stopping antibiotics. However, 
the  diagnostic  value  of  the  clinical  pulmonary  infection  score  has  yet  be 
confirmed. In addition, clinical utility of such a score would be higher if it 
helped clinicians in their decision to initiate or with hold antibiotic therapy in 
patients  clinically  suspected  of  ventilator  associated  pneumonia  rather  than 
only to confirm or exclude pneumonia after 2-3 days when tracheal aspirate 
culture results are available. (2000).
Bacteriologic Strategy
Ioanas A,Ferrer R, Angrill J, Ferrer M, Torres et al84 demonstrated the use 
of  endotracheal  aspirate  in  ventilator  associated  pneumonia  management  is 
increasing,  there  are  few  data  regarding  the  usefulness  of  quantitative  as 
opposed  to  qualitative  cultures.  Some  studies  suggested  that  quantitative 
cultures should be used in  order  to avoid false positive results,  but little  is 
known about the sensitivity and specificity of quantitative culture findings in 
severely ill patients who have previously received broad spectrum antibiotics. 
(2001).
Chastre  J,  Fagon  JY et  al31 studied  that  bronchoalveolar  lavage  can  also 
facilitate  accurate  modification  of  initial  antibiotic  treatment  regimens  for 
ventilator  associated  pneumonia.  The  airway  of  the  mechanically  ventilated 
patient  is  commonly  colonized  with  potentially  pathogenic  bacteria. 
Consequently    obtained  from  endotracheal  or  tracheostomy  tube,  cannot 
consequently  differentiate  between  upper  airway  colonization  and  lower 
respiratory infection. The use of bronchoalveolar lavage for the microbiological 
diagnosis  of  ventilator  associated  pneumonia  appears  to  be  associated  with 
greater confidence amongst clinicians that the culture results actually reflect the 
presence  or  absence  of  ventilator  associated  pneumonia,  together  with  its 
etiology. (2002).
Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kolllef MH et al85 
studied sampling methods that minimize contamination from the upper airway 
(such as bronchoscopic or catheter bronchoalveolar lavage and brushing) help 
to establish a move precise microbiological diagnosis of ventilator associated 
pneumonia to guide subsequent antimicrobial changes. (2001).
Medurai  GU98,  Mauldin  GL,  Wunderink  RG,  Leeper  Jr  KV,  Heyland 
DK82, Cook DJ et al34  showed the bronchoscopic methods bronchoalveolar 
lavage and protected specimen brush are well standarised and widely accepted 
invasive  diagnostic  techniques  for  identifying  the  etiological  pathogen  of 
ventilator  associated  pneumonia.  In  recent  study,  Heyland  et  al  found  that 
invasive diagnostic testing might increase the confidence of physicians in the 
diagnosis  and  management  of   ventilator  associated  pneumonia  as  well  as 
decreased antibiotics usage and lower mortality. (1999).
Rello  J,  Gallego  M,  Mariscal  D,  et  al126 showed  The results  of 
Microbiological  tests  of  sputum  specimens  obtained by  either  invasive  or 
Noninvasive methods are not sufficient for the diagnosis of VAP, but culture 
and sensitivity results can be helpful for choosing an antibiotic. (1997) 
Comparing Diagnostic Strategy
Lambert  R, Vereen L, George R,Sanchez- Nieto JM, Garcia et al96 studied 
Quantitative  Culture of endotracheal aspirate may avoid  false positive results, 
but also provide controversial results, depending on the bacterial load, duration 
of ventilation and prior antibiotic treatment. The sensitivity ranges 38- 100%, 
while  specificity  ranges  14-  100%  using  a  threshold  105-  106 cfu/ml,  the 
sensitivity appears to have narrow range 50- 70% as well as specificity 70- 
85%. Comparing outcome of patients, 2 studies came to the conclusion that 
there  are  no  differences  between  endotracheal  aspirate  and  invasive 
bronchoscopic  methods  in  terms  of  mortality,  ICU  stay,  and  duration  of 
mechanical ventilation. (1989).
Dr  Daren  Heyland  et  al60 report  the  results  of  a  Canadian  multicentre 
randomized trial comparing bronchoalveolar lavage and endotracheal aspirate 
for the diagnosis of ventilator associated pneumonia. The study also addressed 
whether  empiric  antimicrobial  monotherapy  was  equivalent  to  combination 
therapy.  They  concluded  that  utilization  of    bronchoalveolar  lavage  and 
endotracheal aspirate is associated with similar clinical outcomes and overall 
antibiotic utilization. (1999).
Blasi F, Gallego M, Mariscal D, Sonora R, Valles J, Brayan C S, Reynolds 
K  L et  al15 demonstrated  the  rate  of  positive  blood  culture  in  ventilator 
associated pneumonia ranges 8- 20% in critically ill patients, bactereamia is not 
always related to a   pulmonary infection and up to 50% of the patients with 
positive  culture  may  have  an  additional  source  of  infection.  Luna   et  al 
pointed  out  that   blood  culture   in  patients  with   ventilator  associated 
pneumonia are useful to suspect and identify another simultaneous infection 
when  the  microorganisms  isolated  in  blood  does  not  coincide  with  the 
microorganisms isolated respiratory secretion. (1997)
Luna  CM,  Videla  A,  Mattera  J,  Vay  C,  Famiglietti  A,  Vujacich  P, 
Niederman  MS  et  al95 studied  The  spread  of  microorganism  to  blood  or 
pleural  space  is  <10%,  so  blood  and  pleural  effusion  cultures  have  low 
sensitivity and specificity. Luna and colleagues demonstrated that the positive 
predictive value of blood cultures to detect the etiologic microorganism was 
73% and the sensitivity of blood cultures was only 26%. [1997].
TREATMENT
American  Thoracic  Society2  has  stated  that  to  guide  empirical  antibiotic 
choices. These guidelines are divided into those for patients at risk for VAP 
caused by multidrug-resistant organisms and those for patients without such 
risk. In the absence of risk factors for multidrug-resistant bacteria, the clinician 
should choose empirical therapy for Streptococcus pneumoniae, Haemophilus 
influenzae,  methicillin-sensitive  Staphylococcus  aureus,  and  antibiotic-
sensitive  gram-negative  enteric  organisms.  Antibiotic  choices  include 
Ceftriaxone,  quinolones  (levofloxacin,  moxifloxacin,  or  ciprofloxacin), 
Ampicillin/sulbactam, or ertapenem .When risk factors for multidrug-resistant 
organisms are present, the clinician must consider not only the organisms listed 
above  but  also  Pseudomonas  aeruginosa,  Klebsiella,  Enterobacter,  Serratia, 
Acinetobacter,  Stenotrophomonas  maltophilia,  Burkholderia  cepacia,  and 
methicillin-resistant S. aureus.  Empirical  therapy is broadened to include (i) 
either  an  antipseudomonal  cephalosporin  (Cefipime  or  ceftazadime),  an 
antipseudomonal  carbepenem  (imipenem  or  meropenem),  or  a  β-lactam/β-
lactamase  inhibitor  (Piperacillin-tazobactam)  plus  (ii)  an  antipseudomonal 
fluoroquinolone  (ciprofloxacin  or  levofloxacin)  or  an  Aminoglycosides 
(Amikacin, Gentamicin, or tobramycin) plus linezolid or vancomycin. (2005)
 Adair CG, Gorman SP, Byers LM, Jones DS, Feron B, Crowe M, Webb 
HC, McCarthy GJ, Milligan KR et al4 proposed that high concentrations of 
antibiotic on the endotracheal luminal surface, achieved either by nebulizer or 
endotracheal  surface  modification,  would  be  expected  to  prevent  biofilm 
formation  on  the  endotracheal  tube  and  may  have  a  role  in  reducing  the 
incidence of  VAP,  also minimising patient  exposure  to  systemic antibiotics. 
(1995)
 Kress  JP,  Pohlman AS,  O'Connor MF,  Hall  JB et  al94   To reduce the 
aspiration of oropharyngeal contents, over use of sedatives should be avoided. 
Kress et al reported that for reducing over use of sedatives, daily interruption of 
sedative-drug infusions until the patients were awake decreased the duration of 
mechanical ventilation and the length of stay in the ICU. (2000).
GENERAL PROPHYLAXIS
Johanson  WG  Jr,  Pierce  AK,  Sanford  JP,  Mc-Clain  RE  ,Combes  P, 
Fauvage B, Oleyer  C   et al 86     Suctioning the secretions in the trachea is 
another approach to VAP prevention. Two types of tracheal suction catheters 
are used on ventilated patients; the open, single-use catheters and the closed, 
multiple-use  catheters.  In  single-use  system,  HCWs  have  to  use  sterile 
solutions  during  rinsing  these  catheters  and  have  to  care  aseptic  technique 
when  suctioning  endotracheal  secretions.  In  closed  suctioning  systems, 
secretions can be suctioned without removal of mechanical ventilation support. 
This  may  cause  less  hypoxia,  hypotension  and  arrhythmias,  and  also  less 
environmental contamination .However similar VAP rates with closed and open 
system were suggested in the earlier trials ,Combes and colleagues reported a 
3.5 times greater risk of VAP in open suctioning system than closed suctioning 
system in a recent study. Indeed, closed suction catheter is an extension of the 
ventilator circuit, daily change of this catheter is not necessary for infection 
control, and in one study no significant difference in VAP rate was reported 
when daily changes were compared with no routine changes, that may decrease 
the costs .The use of closed suction system is recommended as part of a VAP 
prevention program. (1972)
Craven DE, Steger KA et al49 showed The devices used on the respiratory 
tract come into contact with mucous membranes, therefore cleaning and high-
level  disinfection  (at  75°C  for  30  minutes)  of  reusable  equipments  are 
required.  Resuscitation  bags,  spirometers,  and  oxygen  analyzers  must  be 
cleaned and disinfected between patients to avoid cross-transmission [1984].
Harris  AD,  Samore  MH,  Nafziger  R,  DiRosario  K,  Roghmann  MC, 
Carmeli Y,Albert RK, Condie F et al81 showed Basic hygiene principles of 
infection control (hand washing/disinfection just before and after each patient 
contact,  the  use  of  glove  and  sterile  equipment)  remain  important  for  the 
prevention  of  VAP.  Healthcare  workers  (HCW) can  spread  microorganisms 
from  patient  to  patient  by  their  hands  easily.  Although  HCWs  realize  the 
importance of  hand washing/disinfection,  their  compliance  is  still  low (25–
40%). Especially their compliance rate is lowest in activities that carried higher 
risk for transmission and in ICU. High workload decreases their compliance 
.wrist watches, bangles, and other jewellery act as reservoirs for organisms, and 
inhibits effective hand cleaning. Therefore, staff has to take off wrist watch and 
jewellery  to  achieve  effective  hand  cleaning.  They  have  to  use  gowns  and 
gloves  when  appropriate  and  must  change  and  wash/disinfect  their  hands 
between patients. Bedside hand antiseptics (alcohol-based hand rub solution), 
easier  access  to  sinks  and  availability  of  washing  equipment,  decrease  in 
workload, communication and education tools (posters) and feedback improve 
compliance  and  decrease  the  cross-transmission  of  nosocomial  infection 
[2000].
Drakulovic et al62. found that the simple elevation of the head of bed to 45° 
results in dramatic reductions in VAP incidence and a trend toward reduced 
mortality. Nonetheless, a recent survey by the University Hospital Consortium 
revealed that compliance with the simple and no-cost intervention of elevating 
the head is woefully low, and a study by Heyland et al. revealed that the head 
of bed is on average elevated to 29° and not 45°.  Kinetic bed therapy has also 
led to a reduction in the incidence of VAP (1999).
MATERIALS AND METHODS
 This  is  a  prospective  study where  One hundred patients  admitted into  the 
Respiratory  intensive  care  unit  of  Government  Rajaji  Hospital  attached  to 
Madurai Medical College between May 2008 and December 2008 ( 7 months 
period) were  studied. As per inclusion criteria those patients who were under 
mechanical  ventilation  for  more  than  48  hours  by  endotracheal  tube  or 
tracheostomy  were  evaluated  for  the  development  of  ventilator  associated 
pneumonia.  The Respiratory intensive care unit is equipped with 6 ventilators 
and  central  oxygen.  Each  bed  has  multiparameter  monitor  for  continous 
hemodynamic and respiratory monitoring. Nurse on duty maintain vital sign 
and intake- output record on daily basis. 
             The study was approved by the local ethical committee and separate 
informed  consent  was  obtained  from  each  participant.  For  each  patient,  a 
Proforma  was  filled  out  and  bronchoalveolar  lavage  endotracheal  aspirate 
samples and blood culture were collected and taken immediately for processing 
to the microbiology laboratory.
INCLUSION CRITERIA
1.  A  new  and  persistent  infiltration  in  the  chest  X-ray  in  patients 
mechanically ventilated for more than 48 hrs. 
2. Body temperature above 38.5 or below 36°C. 
3. White cell count above 12,000/μl or below 4000/μl. 
4. Purulent tracheobronchial secretion (TBS). 
5.  Impairment  of  pulmonary  function  as  defined  by  the  PaO2/FiO2  ratio 
> 240. 
6.  Respiratory  tract  infection  with  absence  of  alternative  sources  of 
infection such as urinary tract infection or peritonitis. 
EXCLUSION CRITERIA:
  
 Poor oxygenation (PaO2/FiO2 < 100mmHg)
 Unstable hemodynamic condition.
 Human Immunodeficiency Virus infection.
 Cytotoxic chemotherapy induced neutropenia.
 Organ transplantation.
 Solid and hematological malignancy.
 Patients with tracheal aspirates < 1 ml
DATA COLLECTION:-
Clinically diagnosed Ventilator Associated Pneumonia were observed  and data 
such as age, gender, date of admission into and discharge from the Respiratory 
intensive  care  unit,  risk  factors  involved,  underlying  diseases,  date  of 
intubation/  tracheostomy,  duration  of  mechanical  ventilation  etc.  (copy  of 
Proforma enclosed) were obtained. Time period of Respiratory intensive care 
unit stay prior to initiation of ventilation, duration of Respiratory intensive care 
unit and hospital stays, were also recorded. Days of antibiotic therapy and a 
short  description  of  radiological  findings  were  recorded.  Patients  were 
monitored from the time of inclusion in the study to the date of discharge from 
Respiratory intensive care unit.
Resolution of the disease in the patients was defined as clinical improvement 
accompanied by normal temperature,  decreased volume and transparency of 
tracheobronchial  secretion  and  radiologically  confirmed  elimination  of  the 
infiltrate. 
Once  clinical  suspicion  was  established,  empiric  antibiotic  therapy  was 
initiated. The antibiotics were changed after the quantitative culture results of 
Bronchoalveolar lavage and endotracheal aspirate. 
SPECIMEN COLLECTION 
With each episode of clinically suspected Ventilator Associated Pneumonia, the 
patient was subjected to three different sampling techniques within 12 hours of 
clinical diagnosis of Ventilator Associated Pneumonia with an average of an 
hour between each procedure. A set sequence of sampling was followed in each 
case with the Endotracheal aspirate first,  blood sample and Bronchoalveolar 
lavage at  the last.  All  patients  were premedicated prior to performing these 
sampling procedures unless they were already sedated and paralyzed.
First,  Endotracheal aspirates were obtained with sterile precaution from 100 
patients using a 22-inch, No. 14 Fr suction catheter and collected in a mucus 
collector. A length of approximately 24 cm of the catheter was passed through 
the endotracheal tube, and secretions were aspirated without instilling saline. 
After the catheter was withdrawn, approximately 2-5 mL of saline was injected 
into it  with a sterile syringe to flush the exudate into a sterile container for 
collection. Chest vibration or percussion for 10 min was used to increase the 
retrieved volume (1 mL) in case the patient produced very little  secretions. 
These samples were retrieved for quantitative microbial cultures. Then without 
interrupting mechanical ventilation, through the endotracheal tube and using a 
special  adaptor,  the  fiber  optic  bronchoscope  was  introduced  10  min  later 
without bronchial suctioning after adequate sedation and curarization for 90 
patients, and adjusting ventilator settings to a fraction of inspired oxygen of 
100% with proper rate and tidal volume, a bronchoscope was passed through 
the  endotracheal  tube  via  a  specific  adaptor  without  local  anesthesia.  No 
endobronchial suction was attempted during the advance of the bronchoscope. 
Bronchoalveolar  lavage  sampling  was  obtained  from  the  orifice  of  a  lung 
segment  with  the  most  radiographic  abnormality  or  new  infiltrates,  the 
bronchoscope was then introduced and wedged into the segmental bronchial 
orifice. Seven aliquots of sterile saline (20ml each) were instilled and aspirated 
gently. 
The first two aliquots were discarded, and the last five aliquots were pooled for 
analysis.  Generally  5  mL  of  the  retrieved  BAL  fluid  were  adequate  for 
microbiological  examination. Before the protocol procedures,  blood samples 
were taken for culture from 55 patients with septicaemia.
Blood culture
   The  vein  from which  blood is  to  be  drawn was  selected;  skin  site  was 
disinfected with 70% isopropyl alcohol. About 5ml of blood was collected from 
55 patients and inoculated into 50ml glucose broth (1in 10 dilution). Culture 
bottles were incubated at 35°C for 18 hours. After 18 hrs incubation subculture 
was made aseptically into a nutrient agar, macconkey agar and blood agar. The 
plate was incubated at 35°C for 48 hours. Culture negative bottles were then 
reincubated for 5-7 days.
The  following  thresholds  of  bacterial  cultures  were  used  to  distinguish 
colonization from true infection: ETA, 105 CFU/ml; BAL, 104 CFU/ml. 
MICROBIOLOGICAL METHODS
All  the  samples  were  transported  to  the  laboratory  within  15  minutes  and 
cultured  within  an  hour  of  collection.  After  receipt  in  the  laboratory,  the 
samples were first vortexed for 60 seconds after which, direct examination of 
gram stained  preparations  were  performed  and  studied  for  the  presence  of 
squamous  cells,  polymorphonuclear  cells  and to  differentiate  Gram positive 
and Gram negative bacteria and also yeast cells and their morphology. 
Simultaneously,  quantitative  cultures  using the  calibrated loop method were 
performed  on  common  media  such  as  nutrient  agar,  blood  agar,  and 
Macconkey’s  agar  using standard techniques.  The results  of  the  Gram stain 
were obtained within the first 24 hours and quantitative cultures were obtained 
within the following 48 to 72hours. In patients with repeated incidence of VAP 
symptoms, a repeat culture was performed.
Microbiological  examination  for  unusual  organisms  such  as  leigeonella, 
Mycoplasma, Chlamydia, Pneumocystis carinii, anaerobes and viruses did not 
form a part in this study.
MICROBIOLOGICAL PROCESSING
AEROBIC CULTURE
ETA and BAL samples were mechanically homogenized using glass Beads and 
were vortexed for 1 min.. The samples were then serially diluted in 0.9% sterile 
saline solution with final dilutions of 10-2, 10-3 and 10-4 for ETA and 10-1, 10-2 
and 10-3 for BAL. ETA and BAL were mixed 1:1 with sterile normal saline. 
Thereafter,  100 micro liters  were  inoculated into the  following agar  media: 
Nutrient  agar,  5%  sheep  blood,  and  Macconkey  agar.  All  cultures  were 
incubated at 37° C under aerobic atmosphere. 
Cultures were evaluated for growth 24 hrs and 48 hrs later and discarded, if 
negative, 5 days after. The next day, aerobic cultures were examined for the 
growth of organisms. The plates which showed growth were studied by colony 
morphology, gram reaction and motility (hanging drop). 
BIOCHEMICAL REACTIONS
They  were  then  subjected  to  biochemical  tests  for  identification.  Catalase, 
Coagulase and oxidase tests were performed. A single colony was inoculated 
into peptone water which was used as inoculum for the following biochemical 
test
 Indole 
 TSI
 Christensen’s urease medium
 Simmon’s citrate utilization test
 MR
 VP
 Nitrate reduction test
All microorganisms isolated were identified by standard laboratory methods. 
Results are expressed as colony forming units per milliliter (CFU/ ml = number 
of colonies × dilution factor × inoculation factor). 
 After initial characterisation of the isolates by colony morphology and Gram 
stain, species identification and susceptibility testing were done
ANTIBIOTIC SUSCEPTIBILITY TEST
It  was performed by Kirby-bauer standard disc diffusion method on Muller-
Hinton agar for all isolates. The organism inoculated into peptone water was 
incubated for half an hour and Muller-Hinton agar was seeded by pour plate 
method. The excess was pipetted off, the plate allowed to dry and antibiotic 
discs  (commercially  available)  were  placed  and  incubated  for  18-  24  hrs. 
Following  over  night  incubation  the  plates  were  examined  for  the  zone  of 
inhibition around the drug disc is  measured with a scale and the sensitivity 
pattern  of  the  isolates  were  studied.  The  following  were  the  commercial 
antibiotic discs employed.
Ampicillin  (10 μg), inj. Gentamicin (10 μg), trimethoprim / sulphamethazole 
(1.2 μg / 23.8 μg), ciprofloxacin (1 μg), Cephalexin (30 μg), Cefotaxime (10 
μg),  Ceftriaxone  (10  μg),  Amikacin  (30  μg),  Doxycycline  (30 μg), 
erythromycin  (5  μg), Piperacillin/  tazobactam (100  μg/10  μg), Carbencillin 
(100  μg), tobramycin  (10  μg),  Ofloxacin  (5  μg),  Gatifloxacin  (5  μg), 
Cloxacillin(1 μg), Cefipime(30 μg), oxacillin (5 μg).
FUNGAL CULTURE
 
The  standard  media  for  primary  isolation  of  fungus  namely  Sabouraud’s 
dextrose agar, containing Gentamicin and cycloheximide was used. ETA and 
BAL samples were inoculated onto Sabouraud’s dextrose agar. The inoculated 
slant was incubated at 37° C. The cultures were maintained for 30 days before 
discarding them as negative. 
When  growth  became  evident  on  the  primary  isolation  media,  fungi  were 
identified macroscopically  on the basis  of colony appearance,  pigmentation, 
consistency and microscopically by the appearance of conidia.
 
For observing the microscopic appearance, using teasing needle, mounts from 
the culture were made in Lacto phenol cotton blue and gram staining.
INTERPRETATION OF QUANTITATIVE CULTURE 
RESULTS
The  diagnostic  thresholds  for  ETA and  BAL were  taken  as  105cfu/ml  and 
104cfu/ml respectively. Growth below the threshold was assumed to be due to 
colonization or contamination. For Gram stain results  the thresholds for the 
diagnosis  of  VAP with  the  ETA and  BAL samples  were  as  follows:  >  10 
polymorphonuclear neutrophils (PMN) / high-power field (HPF), ≥ 1 bacteria / 
oil immersion field (OIF), presence of intracellular bacterial inclusions.
PATIENT FOLLOW-UP
All patients with positive quantitative cultures of ETA / BAL were treated as 
per the antibiogram reports obtained. After the modification of antibiotic drug 
regimen, these patients were followed up to exclude other diagnoses. VAP was 
considered to  have occurred in  those patients  when there  was a  correlation 
between the positive culture result and the clinical outcome.
RESULTS
 In the study period of seven months, there were a total of 215 Respiratory 
intensive care unit admissions at Government Rajaji Hospital Madurai where 
the study was made.176 (81.8%) patients were mechanically ventilated and 152 
patients  among  them (70.7%)  were  ventilated  for  more  than48  hours.  One 
Hundred patients among 152(46.5%) were with clinical pulmonary infection 
score more than six. Only these patients who were mechanically ventilated for 
> 48 hrs with CPIS score > 6, considered as Ventilator Associated Pneumonia 
were included in this study. 
From these 100 patients, two hundred and forty five samples were collected. 
The  samples  included  one  hundred  endotracheal  aspirates,  ninety  broncho 
alveolar lavages    and fifty-five blood cultures. Sample wise distribution is 
given in table no.1 
TABLE 1
SAMPLE WISE DISTRIBUTION
Total no. of 
samples (n)
Sample wise distribution Percentage (n) 
%
       245
Endotracheal aspirate
Bronchoalveolar lavage
Blood culture
100(40.8%)
90(36.7%)
55(22.4%)
 The  Sex and age distribution  of these cases were  studied and it was found 
that,  out of  One hundred  patients,  68 (68%)  patients  were  males and  32 
(32%)  were  females.  Out of 68 male patients, 2(2.9%) were in the age group 
0-20 years, 50 (73.5%) were 21- 40 years, 14 (20.6%) were 41- 60 years and 
2 (2.9%) were > 60 years.  Out of 32 female patients, 4 (12.5%) were 0-20 
years, 16 (50%) were 21- 40 years, 10 (31.3%) were 41- 60 years and 2(6.3%) 
were > 60 years.  It was found that infection rate in Ventilator Associated 
Pneumonia  was  more  common  in  males  than  in  females  and  the 
Predominant age group was 21- 40 years, in both males and females. Age 
and sex wise distribution of cases are shown in table no.2
TABLE 2
DEMOGRAPHIC DATA OF PATIENTS INVESTIGATED
Sl.No Age wise distribution Male (68)
n=68
Female (32)
n =32
1.     0-  20 years 2   (2.9%) 4   (12.5%)
2.    21- 40 years 50 (73.5%) 16 (50%)
3.    41- 60 years 14 (20.6%) 10 (31.3%)
4.       > 60 years 2   (2.9%) 2 (6.3%)
All   One hundred patients were further analysed according to the   clinical 
conditions and it was found that 44 (44%) were poisoning cases, 24 (24%)with 
abdominal surgeries,  12(12%)  were  suffering from  guillian barre syndrome, 
8 (8%)  had history of   snake bite,  4 (4%)  had  head trauma, multiple injuries  
and   diabetic Ketoacidosis.  It was observed that incidence of Ventilator 
Associated Pneumonia was more in poisoning cases followed by abdominal 
surgeries. This   is given in table no.3
                          
TABLE 3
DISTRIBUTION OF CASES Vs CLINICAL CONDITIONS
Sl.NO Clinical conditions Number of patients
1.      Poisoning 44 (44%)
2.     Abdominal surgery 24 (24%)
3.     Gullian barre syndrome 12 (12%)
4.      Snake bite 8 (8%)
5.      Diabetic Ketoacidosis 4(4%)
6.      Head trauma 4 (4%)
7.      Multiple injuries 4 (4%)
Endotracheal aspirate: - Out of 100 endotracheal aspirate samples collected 
from clinically  suspected  Ventilator  Associated  Pneumonia  cases,  90  (90%) 
samples yielded growth on culture.  There were 112 isolates totally as some 
cultures yielded more than one isolates. These 112 isolates were subjected to 
gram staining and it was found that out of 112 isolates 80 (71.4%) were Gram 
negative  bacteria,  18  (16.1%) were  Gram positive  bacteria  and 14 (12.5%) 
were fungi. Thus  it was  observed that  more cases of ventilator associated 
pneumonia  were  caused  by  Gram  negative  organisms  ,  than   Gram 
positive  organisms. This is given in table no.4
TABLE 4
GRAM REACTION OF ISOLATES OF
ENDOTRACHEAL ASPIRATES
Total no of isolates Etiological agents Percentage (n) %
      112
Gram negative bacteria
Gram positive bacteria
Fungus
80(71.4%)
18(16.1%)
14(12.5%)
The 112 isolates were further subjected to genus identification and it was found 
that out of 112 isolates, 32(28.6%) were Pseudomonas aeruginosa,21(18.8%) 
were  Klebsiella  pneumoniae,  9(8%)  were  Klebsiella  oxytoca,  14(12.5%) 
were  Staphylococcus  aureus,  4(3.6%)  were  Coagulase  negative 
Staphylococci,  Acinetobacter  and  Enterobacter,  2(1.8%)  were  Citrobacter 
freundi  and  koseri,  3(2.6%)    were  Proteus  mirabilis  and  Escherichia  coli, 
12(10.7%) were Candida species and 1(0.8%)  was Aspergillus fumigatus and 
Aspergillus  niger.   Thus  it  was  proved  that  among  gram  negatives 
Pseudomonas aeruginosa and Klebsiella pneumoniae were common and 
Among the Gram positives Staphylococcus aureus was common. Among 
fungi Candida species was common. This is given in figure no.3
                                  
Quantitative analysis  of  112 positive isolates showed that,  colony counts of 
>105 cfu/ml were present in 85 (75.9%) isolates, colony count between 104 and 
105    were seen in 16 (14.3%) isolates and colony count between 103 and 10 4 
cfu/ml  were  seen  in  11(9.8%)  isolates.   It  was  observed  that  75.9%  of 
positive isolates showed colony count >105 cfu/ml,  which is  a diagnostic 
threshold for endotracheal aspirates. This is given in table no. 5
TABLE 5
QUANTITATION OF ENDOTRACHEAL ASPIRATES
Sl.No Quantitation No of isolates Percentage (%)
2. >105 cfu/ml 85 75.9%
3. 104  - 105 cfu/ml 16 14.3%
4. 103 - 104 cfu/ml 11 9.8%
Quantitation of culture  was analysed organism wise and it was found that, Out 
of  85  isolates  with  colony  counts  of   >105  cfu/ml  ,   35(41.2%)  were 
Pseudomonas  aeruginosa  isolates,  21(24.7%)  were  Klebsiella   Pneumoniae 
isolates,   16(18.8%)  were  Staphylococcus  aureus  isolates,  11(12.9%)  were 
Klebsiella oxytoca  isolates and  2(2.4%) were Enterobacter  isolates.  Out of 
16  isolates  with  colony  count  between  104 and    105,  4(25%)  each  were 
Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli and Proteus
mirabilis.  Out of 11 isolates with colony count between103 and 104 cfu/ml, 
5(45.5%) were Coagulase negative staphylococci isolates and 3(18.2%) each 
were  Citrobacter  Sps  and  Acinetobacter  Sps.   Quantitation  revealed  that 
Pseudomonas  aeruginosa,  Klebsiella  pneumoniae  and  Staphylococcus 
aureus showed colony counts of diagnostic threshold. This is given in table 
no.6
                              
TABLE 6
QUANTITATION Vs ORGANISMS IN
ENDOTRACHEAL ASPIRATE
Quantitation No of positive 
isolates
Isolates %  Percentage
>105 cfu/ml 85 Pseudomonas aeruginosa
Klebsiella pneumoniae     
Staphylococcus aureus
Kl.oxytoca
Enterobacter
35 (41.2%)
21 (24.7%)
16 (18.8%)
11 (12.9%)
2 (2.4%)
104  - 105 cfu/ml 16 Pseudomonas aeruginosa
Klebsiella pneumoniae     
Escherichia coli
Proteus mirabilis
4 (25%)
4 (25%)
4 (25%)
4 (25%)
103 - 104 cfu/ml 11 CONS
Citrobacter Sps 
Acinetobacter Sps
5 (45.5%)
3 (18.2%)
3 (18.2%)
Bronchoalveolar  lavage:-  :-   Out  of  90 Bronchoalveolar  lavage samples 
collected clinically suspected Ventilator Associated Pneumonia cases, 81(90%) 
samples  yielded Growth on culture.  There  were  98 isolates  totally  as some 
cultures yielded more than one organisms. These 98 isolates were subjected to 
Gram staining and it was found that out of 98 isolates, 69(70.4%) were Gram 
negative bacteria, 15(15.3%) were Gram positive bacteria and 14(14.3%) were 
fungi.  Thus it was found that there was more number of Gram negative 
bacteria  in  bronchoalveolar  lavage,  causing  ventilator  associated 
pneumonia than Gram positive bacteria. This is given in table no.7
                                 
TABLE 7
GRAM REACTION OF ISOLATES OF
BRONCHOALVEOLAR LAVAGES 
Total no of isolates Etiological agents Percentage (n) %
     98
Gram negative bacteria
Gram positive bacteria
Fungus
 69(70.4%)
 15(15.3%)
 14(14.3%)
The  98 isolates  were further  subjected to genus identification and it  was 
found  that  out  of  98  isolates,  28(28.6%)  were  Pseudomonas 
aeruginosa,15(15.3%)  were  Klebsiella  pneumoniae,  10(10.2%)  were 
Klebsiella oxytoca,  11(11.2%) were Staphylococcus aureus,  4(4.1%)  were 
Coagulase  negative  staphylococci,  Acinetobacter  Species  and  Enterobacter, 
2(2%)  were  Proteus  mirabilis,  Citrobacter  freundi,  Citrobacter  koseri  and 
Escherichia coli, 12(12.2%) were Candida species and 1(1%) was Aspergillus 
fumigatus and Aspergillus niger.   Thus it was observed that among gram 
negatives,  Pseudomonas aeruginosa and Klebsiella  pneumoniae was the 
common and among gram positives, Staphylococcus aureus was common 
organism isolated.  Among fungi,  Candida species was common. This is 
given in figure no.4
                              
Quantitative analysis of 98 positive isolates showed that, colony count of >105 
cfu/ml  were  present  in  7(7.1%)  isolates,  colony  count  between  104  and 
105cfu/ml were seen in 83(84.7%) isolates and Colony count of between 103  – 
104 cfu/ml were  seen in  8(8.2%) isolates.  It  was observed that  84.7% of 
positive isolates showed colony count  between 104 - 105 cfu/ml which is a 
diagnostic yield for bronchoalveolar lavage.  This is given in table no. 8
TABLE 8
QUANTITATION OF BRONCHOALVEOLAR LAVAGES
Sl.No Quantitation No of isolates Percentage (%)
1. >105 cfu/ml 7 7.1%
2. 104  - 105 cfu/ml 83 84.7%
3. 103  - 104 cfu/ml 8 8.2%
Quantitation of  culture was  analysed organisms wise and it was found that, 
out of 83 isolates with  colony count  between  104  - 105 cfu/ml, 30(36.1%)were 
Pseudomonas  aeruginosa   isolates,  17(20.5%)  were  Klebsiella  pneumoniae 
isolates,  13(15.7%) were   Staphylococcus  aureus isolates, 12 (14.5%)  were 
Klebsiella oxytoca isolates, 4(4.8%) were  Enterobacter  and Escherichia coli 
isolates, 2(2.4%) were proteus mirabilis and 1(1.2%) was Acinetobacter Sps. 
Out of 8 isolates with Colony  count   between 103  and   104  , 4(50%)   were 
Coagulase negative staphylococci, 2(25%) each were seen in Citrobacter Sps 
and Acinetobacter Sps. Out of 7 isolates with  Colony count of 
>105 cfu/ml, 4(57.1%) were Pseudomonas aeruginosa isolates, 2(28.6%) were 
Klebsiella  pneumoniae  isolates  and  1(14.3%)  was  Staphylococcus  aureus 
isolates.  It  was  observed  that  Pseudomonas  aeruginosa,  Klebsiella 
pneumonia and Staphylococcus aureus showed colony counts of diagnostic 
threshold. This is given in table no.9
TABLE 9
QUANTITATION Vs ORGANISMS IN
BRONCHOALVEOLAR LAVAGE
Quantitation No of positive 
isolates
Isolates %  Percentage
103 - 104 cfu/ml 8 CONS
Citrobacter Sps
Acinetobacter Sps
4 (50%)
2 (25%)
2 (25%)
104  - 105 cfu/ml 83 Pseudomonas aeruginosa
Klebsiella pneumoniae     
Staphylococcus aureus
Kl.oxytoca
Escherichia coli
Proteus mirabilis
Enterobacter 
Acinetobacter Sps
30(36.1%)
17(20.5%)
13(15.7%)
12(14.5%)
4(4.8%)
2(2.4%)
4(4.8%)
1(1.2%)
>105 cfu/ml 7 Pseudomonas aeruginosa
Klebsiella pneumoniae     
Staphylococcus aureus
4(57.1%)
2(28.6%)
1(14.3%)
Blood culture:  A total of fifty five blood samples were collected from patients 
of clinically suspected Ventilator Associated Pneumonia with septicaemia for 
non enteric blood culture. Out of 55 samples, 16 cultures yielded growth.
There were 20 isolates from these 16 cultures as some cultures yielded more 
than one organisms. These isolates were subjected to gram staining and it was 
found that, out of 20 isolates 13(65%) were Gram negative bacteria, 5 (25%) 
were Gram positive bacteria and 2 (10%) were fungus.  It was observed that 
there  were  more  number  of  Gram  negative  isolates  in  blood  culture, 
causing ventilator associated pneumonia than Gram positive isolates. This 
is given in tableno.10
TABLE 10
GRAM REACTION OF ISOLATES IN
BLOOD CULTURE
Total no of isolates Etiological agents Percentage (n) %
      20
Gram negative bacteria
Gram positive bacteria
Fungus
 13(65%)
 5(25%)
 2(10%)
The 20 isolates were analysed for varied organisms and it was found that, Out 
of  20  isolates,  6(  30%)  were  Pseudomonas  aeruginosa,  5(25%)  were 
Staphylococcus  aureus,  4(20%)  were  Klebsiella  pneumoniae,  2(10%)  were 
Escherichia coli, 1(5%) were Klebsiella oxytoca  and 2(10%) were Candida 
species.  It was found that the most common organism  isolated  among 
gram negative was Pseudomonas aeruginosa  (30%) among gram positive 
was staphylococcus aureus and among fungi Candida species. This is given
in table no.11.       
                                         
                                                TABLE 11
PATHOGENS ISOLATED FROM BLOOD CULTURE
Total No of 
isolates Organisms isolated No .of each isolates
Percentage 
%
       20
Pseudomonas aeruginosa  
Staphylococcus aureus
Klebsiella pneumoniae
Escherichia coli
Klebsiella oxytoca  
Candida species
6
5
4
2
1
2
30
25
20
10
5
10
Correlation of lab reports with clinical condition
In  patients  with  Poisoning,  Pseudomonas  aeruginosa  13(29.5%)  was 
predominantly  isolated.   In  Abdominal  surgeries,  Klebsiella  pneumonia 
12(50%) and Pseudomonas aeruginosa 9 (37.5%) were predominantly isolated. 
In  Guillian  barre  syndrome,  Pseudomonas  aeruginosa  7(66.6%)  was 
predominantly  isolated.  In  Snake  bite,  Staphylococcus  aureus  2(25%)  and 
Coagulase Negative Staphylococcus2 (25%) were predominantly isolated. In 
Diabetic Ketoacidosis,  Pseudomonas aeruginosa 2 (50%) was predominantly 
isolated. In Head trauma, Klebsiella pneumoniae and Staphylococcus aureus 
were  isolated.   In  Multiple  injuries,  Staphylococcus  aureus  3(75%)  was 
predominantly  isolated.  Pseudomonas  aeruginosa  was  the  common 
organism causing Ventilator Associated Pneumonia and was isolated from 
Poisoning, Guillian barre syndrome and Diabetic Ketoacidosis cases and in 
this  study  was  isolated  more  frequently  (66.6%)  from  patients  with 
Guillian barre syndrome. This is shown in table no 12.
                             
TABLE 12
ORGANISMS ISOLATED Vs ETIOLOGY
Isolates Poisoning
(44)
No.        %
Abdominal 
surgery(24)
No.        %
Gullian 
barre 
syndrome
(12)
No.        %
Snake 
bite(8)
No.   % 
Diabetic 
Ketoacidosi
s
(4)
No.        %
 Head 
trauma
(4)
No.   % 
Multiple 
injuries
(4)
No.   %     
Ps.aeruginosa 13      29.5 9           37.5 7        66.6 0       0 2          50 0       0 0        0
Kl.pneumoniae  4         9.1 12         50 2        16.7 0        0 1          25 1      25 1       25
Kl.oxytoca  3         6.8  5          20.8 1          8.3 0        0 0            0 0        0 0        0
S.aureus 4          9.1 3           12.5 1          8.3 2      25 0            0 1      25 3        75
CONS 2          4.5 0             0 0           0 2      25 0            0 0        0 0        0
Acinetobacter 2          4.5 0             0 1          8.3 0        0 1          25 0        0 0        0
Citrobacter 2          4.5 1            4.2 0           0 1   12.5 0            0 0        0 0        0
Proteus 
mirabilis
0             0 3           12.5 0           0 0        0 0            0 0        0 0        0
Escherichia coli 0             0 2            8.3 0           0 0        0 0           0 1      25 0        0
Candida sps 6         13.6 3           12.5 2        16.7 0        0 0           0 0       0 1       25
Aspergillus sps 0             0 0                0 2        16.7 0       0 0            0 0        0 0         0
Comparing all the three techniques of diagnosing infectious agent in ventilator 
associated  pneumonias,  it  was  found  that  endotracheal  aspirate  and 
bronchoalveolar lavage yielded more isolation (90% in each) than blood culture 
(29%). This is given in table no. 13
TABLE 13
COMPARISION OF DIFFERENT TECHNIQUES
Investigation Performed No of culture 
positive cases
% Positivity
Endotracheal 
aspirate
100 90 90
Bronchoalveolar 
lavage
90 81 90
Blood culture 55 16 29
There was total agreement   between culture results of endotracheal aspirate 
and  bronchoalveolar  lavage  techniques  whereas  blood  culture  showed  less 
positivity rate.  
Antimicrobial Susceptibility:-
Drug sensitivity pattern for the various bacterial isolates were analysed. 
Pseudomonas aeruginosa showed resistant to Gentamicin (61.9 %), Ceftriaxone 
(79.7%),  Ciprofloxacin  (56.2%),  Ofloxacin  (62.5%),  Amikacin  (20%), 
Piperacillin tazobactam (62.5%), Cefipime (68.7%) and Carbencillin (76.6%) 
and 100% resistant to Ampicillin, Cephalexin, Cefotaxime, Cotrimoxazole and 
Doxycycline.
Staphylococcus  aureus  were  resistant  to  Gentamicin  (75.9%),  Ceftriaxone 
(86.2%),  Ciprofloxacin  (72.5%),  Ofloxacin  (79.4%),  and  100% resistant  to 
Ampicillin, Cephalexin, Cefotaxime, Cloxacillin, Cotrimoxazole, Doxycycline, 
Erythromycin and Oxacillin.
Klebsiella pneumoniae showed resistant to Gentamicin (47.4%), Ceftriaxone 
(60.5%),  Ciprofloxacin (47.4%),  Ofloxacin (52.6%),  Piperacillin  tazobactam 
(52.6%),  Cefipime (57.9%) and Carbencillin  (68.5%) and 100% resistant to 
Ampicillin, Cephalexin, Cefotaxime, Cotrimoxazole and Doxycycline.
Escherichia  coli  showed  100  %  resistant  to  Ampicillin,  Cephalexin, 
Cefotaxime,  Cotrimoxazole,  Doxycycline,  Gentamicin,  Ceftriaxone, 
Carbencillin, and Cefipime.
Proteus  mirabilis  showed  100  %  resistant  to  Ampicillin,  Cephalexin, 
Cefotaxime, Cotrimoxazole, Doxycycline, Gentamicin, Ofloxacin, Piperacillin 
tazobactam, Carbencillin, and Cefipime.
Acinetobacter showed resistant to Gentamicin (87.5%), Cotrimoxazole (75%), 
and  100  %  resistant  to  Ampicillin,  Cephalexin,  Cefotaxime,  Doxycycline, 
Ofloxacin,  Ciprofloxacin,  Ceftriaxone,  Piperacillin-tazobactam  Carbencillin, 
Cotrimoxazole and Cefipime. 
Citrobacter  showed resistant  to  Gentamicin  (87.5%),  Ciprofloxacin  (87.5%) 
and  100  %  resistant  to  Ampicillin,  Cephalexin,  Cefotaxime,  Doxycycline, 
Ofloxacin,  Ciprofloxacin,  Ceftriaxone,  Piperacillin-tazobactam,  Carbencillin, 
Cotrimoxazole and Cefipime.
All the isolates were sensitive to Gatifloxacin, and Aminoglycosides group of 
drugs  (80%).  Resistance  was more commonly  observed among beta  lactam 
group of antibiotics for all isolates. This is shown in table no.14
 It was observed that 75 % of Pseudomonas aeruginosa   isolated were 
multidrug resistant, 69% of Klebsiella pneumonia was multi drug resistant 
and   100% of Staphylococcus aureus isolates were resistant to methicillin 
(MRSA).
Mortality and morbidity:
 With regard to  the  mechanical  ventilation  period,  patients  were  artificially 
ventilated for 15 ± 5 days. Average duration of stay in Respiratory Intensive 
Care Unit was 15± 5 days.
The crude observed mortality rate was 26% (26 of 100 cases).  Mortality rate 
was determined based on the duration of respiratory care unit stay and isolation 
of organisms. Out of 26 deaths, 2 (7.7%) deaths were seen in 5 days RICU stay, 
8 (30.8%)   were seen in 10 days stay, 13(50%) were seen in 15 days stay, 
3(11.5%) were seen in 20 days stay.  It was observed that more number of 
deaths was seen in 15 days RICU stay. This is given in table no.15
TABLE 15
OUTCOME IN PATIENTS WITH VENTILATOR
ASSOCIATED PNEUMONIA
Total no of death RICU Stay 
duration
Number of 
deaths
Percentage
       
26
5 days
10 days
15 days
20 days
2
8
13
3
7.7 %
30.8 %
50 %
11.5 %
Mortality as per organism isolated were evaluated and it was found that 18 out 
of  26 deaths showed  Pseudomonas aeruginosa (69.2%) in all 3 samples, 4 
showed  Klebsiella pneumoniae (15.4%),  2  showed Staphylococcus aureus 
(7.7%)  and   Aspergillus  growth  (7.7%).  Mortality  increased  in  patients 
infected  with Pseudomonas aeruginosa  which  invariably  is  multidrug 
resistance.  This is given in table no.16
                                 TABLE 16
MORTALITY IN VENTILATOR 
ASSOCIATED PNEUMONIA
Total no of 
death
Causative agent Number 
of deaths
Percentage
26
Pseudomonas aeruginosa
Klebsiella pneumoniae
Staphylococcus aureus
Aspergillus
18
 4
 2
 2
69.2%
15.4%
7.7%
7.7%
DISCUSSION
The present   study was carried out to find out the various factors involved in 
Ventilator Associated Pneumonia among 100 patients who were admitted in 
Respiratory Intensive Care Unit of Government Rajaji Hospital on mechanical 
Ventilation.  The  cases  included  in  the  study  were  Poisoning,  Abdominal 
surgeries,  Gullian  barre  syndrome,  Snake  bite,  Diabetic  Ketoacidosis,  Head 
trauma  and  multiple  injuries.  The  study  period  was  from  May  2008  to 
December 2008.
In the present study it was found that 68% of the cases were males and 32% 
were females. Thus the infection rate was found to be more common in males 
than in females. Similar study by cook DJ et al 42(62%) and Cook and Kollef 
91(56%)  also  identified  male  gender  dominance  in  Ventilator  Associated 
Pneumonias.  As in these studies, the male dominance seems to be with patient 
specific demographic characteristics in this study also.
In the present study, age group commonly involved in Ventilator Associated 
Pneumonia  was between 21-  40 years,  and the  important  clinical  condition 
involved  in  mechanical  ventilation  was  poisoning  cases  (44%)  especially 
suicidal poisonings. Similar study by Han SC et al80 revealed that 45.6% of the 
poisoning  cases  in  mechanical  ventilation  developed  Ventilator  Associated 
Pneumonia. Panwar et al 111in his study showed 34 years as the common age 
group involved in Ventilator Associated Pneumonias associated with poisoning
cases. These two studies are in accordance with this present study. Most of the 
poisoning  cases  were  subjected  to  gastric  lavage  prior  to  admission.  These 
patients  had  signs  of  severe  respiratory  disease  and  increased  need  for 
mechanical  ventilation;  hence increase in Ventilator  Associated Pneumonias. 
The pulmonary symptoms might be due to aspiration as a result of induced 
vomiting and lavage.  As most of the poisoning cases were in the age group 21- 
40 years, Ventilator Associated Pneumonias shown to be common in this age 
group.
In  the  present  study,  71.4%  Gram  negative  organisms  were  isolated  in 
Ventilator Associated Pneumonias. Among the Gram negative isolates, 28.6% 
were Pseudomonas aeruginosa and 18.8% were Klebsiella  pneumonia.  Both 
these organisms had quantitatively showed diagnostic threshold. Similar study 
by  Rajesh  chawla  et  al  119also  found that  87% of  patients  with  Ventilator 
Associated  Pneumonia  were  infected  with  Gram  negative  bacilli,  most 
commonly Pseudomonas aeruginosa (30%) and Klebsiella pneumonia (20%), 
which are in support  of  this  study.  It  has  been known for  decades  that  the 
microbial  flora of hospitalized and critically ill  patients  becomes drastically 
altered within days after admission. In these patients, usual low virulent mixed
flora of oropharynx and anaerobic flora of the colon become overgrown by 
endogenous aerobic gram negative bacilli, which can then colonize the airway 
and lead to lung infection. This may be the reason for increased incidence of 
gram negative organisms in this study also.           
In this study, Pseudomonas aeruginosa and Candida were commonly presented 
in patients with Guillian barre syndrome, poisoning, abdominal surgeries and 
diabetics.  Guillian  barre  syndrome  is  an  autoimmune  disease,  in  which 
corticosteroids played a major role and patients were in mechanical ventilation 
for  prolonged  periods  and  these  might  be  the  main  risk  factors  related  to 
Pneumonia  by  Pseudomonas  aeruginosa and Candida  in  these  patients.  The 
virulent factor, type 3 secretory Exotoxin secreted by nosocomial Pseudomonas 
could  also  be  another  factor  causing  Pneumonia  by  Pseudomonas  in  these 
patients on mechanical ventilation.
In the present study, among Gram positive organisms, Staphylococcus aureus 
accounted for 12.5% and all were methicillin resistant. Similar study by Riza et 
al124 showed methicillin resistant Staphylococcus aureus (30.4%) as the most 
frequently  isolated  organism.   Kollef  MH et  al91,  Tejada  Artigas  et  al141, 
Torres A et al138, Akca O et al  6in their studies showed that Staphylococcus 
aureus was the predominant gram positive organism in Ventilator Associated 
Pneumonias.  In this study Staphylococcus aureus was mostly seen in multiple 
injuries and all the isolated staphylococcus aureus were methicillin resistant.  It 
was observed that the injured patients were administered antibiotics, on the day 
of admission itself even before mechanical ventilation and the samples from 
these patients were collected 4-6 days after mechanical ventilation.  Most of 
these patients stayed in the hospital for more than 10 days. Prolonged usage of 
antibiotics and prolonged hospital stay on mechanical ventilation might be the 
reasons for resistant organisms.   It  is presumed that  most of the strains of 
staphylococcus  aureus  might  be  community  acquired  with  toxin  producing 
capacity associated with aggressive virulent skin and soft tissue infections and 
necrotizing pneumonia.
It has been shown in this study that 75.9% of Endotracheal aspirate samples 
yielded  bacterial  count  >105   Cfu/ml.  Remaining  samples  showed  bacterial 
count  between 103-  104 cfu/ml.  Similarly  84.7% of  Bronchoalveolar  lavage 
samples  yielded  threshold  of  >104 cfu/  ml.  Remaining  samples  showed 
bacterial count between 103- 104 cfu/ml. The Quantitative endotracheal aspirate 
and bronchoscopy including Broncho alveolar lavage achieved a very similar 
yield with regards to diagnostic threshold, proving that both techniques yielded 
equal amount of organisms for diagnosis of  Ventilator Associated Pneumonia 
in these cases.   Similar study by  Timsit et al140 revealed that  no difference 
found  when  either  invasive  (BAL)  or  Quantitative  Endotracheal  Aspirate 
(QEA)  techniques  were  used  to  diagnose  Ventilator  Associated  Pneumonia. 
Most  studies  have  concluded  that  the  diagnostic  accuracies  of  non 
bronchoscopic  and  bronchoscopic  techniques  were  similar.  This  is  because 
even  though  the  technique  of  obtaining  specimen  varies  (invasive, 
noninvasive), the ultimate specimen obtained for diagnosis was the same that is 
the lung secretions. Hence no variation in the yield. All the cases in this study 
had clinical features of pneumonia, irrespective of threshold value, proving that 
the cases with threshold below the accepted value could be an early phase of 
infection. 
The rate of positive blood culture in the present study was 29%. Similar study 
by  Ioanas et al  84showed that the rate of positive blood culture in Ventilator 
Associated Pneumonia was 20% and the study by Steven et al 130also revealed
that blood culture positivity was 25%. These studies support the findings of the
present study. As most of the patients were administered antibiotics on the day 
of admission and the blood samples were collected after therapy, there might be 
low positivity for blood culture. Hence the role of blood culture is limited in 
the study of Ventilator Associated Pneumonia.
In this study it  was also noted that organisms isolated in the three types of 
samples (ETA, BAL, Blood culture) were the same in all these cases, showing 
that  all  these cases were only pulmonary infection,  not associated with any 
additional source of infection. Luna et al95 showed in his study 50% of patients
with  Ventilator  Associated  Pneumonia  were  with  some  other  simultaneous 
infection,  because organism isolated in  blood culture  did not  coincide with 
isolates in respiratory secretion.  
In this study, it was shown that an overall rate of 75% Pseudomonas aeruginosa 
were multidrug resistant. Pseudomonas aeruginosa was resistant to Gentamicin 
(61.9%),  Ceftriaxone  (79.7%),  Ciprofloxacin  (56.2%),  Ofloxacin  (62.5%), 
Amikacin  (20%),  Piperacillin  tazobactam  (62.5%),  Cefipime  (68.7%)  and 
Carbencillin  (76.6%),  and  100%  resistant  to  Ampicillin,  Cephalexin, 
Cefotaxime, Cotrimoxazole, and Doxycycline. Similar study  Arindam et al 9 
also showed 48% of pseudomonas aeruginosa were multidrug resistant. This 
correlates  with  present  study.  In  this  study  Pseudomonas  aeruginosa  was 
susceptible for Gatifloxacin and Amikacin. Increased resistance might be due 
to various factors like prolonged usage of antibiotics, prolonged hospital stay or 
by  the  liberation  of  either  IMP- type metalloenzymes or  carapenemases  by 
pseudomonas.
In present study Klebsiella Sps also played a major role in producing resistance 
(69%)  for  many  antibiotics,  as  Klebsiella  can  produce  ESBL,  which  are 
typically  plasmid  mediated  and  clavulanate  susceptible  enzymes,  that 
hydrolyze penicillins, expanded spectrum cephalosporins and aztreonam.
All  the  isolates  of  staphylococcus  aureus  were  resistance  for  methicillin 
(100%),  showing  that  MRSA was  the  most  frequent  causative  agent  for 
Ventilator Associated Pneumonia.  Arindam et al9 showed more isolates of 
MRSA in their  study,  and explained that  these  resistance pathogens always 
varied in different set up. Occurrence of resistance for multiple drugs in these 
patients  might  be  one  of  the  major  reasons  for  Ventilator  Associated 
Pneumonia.
In present study it was found that the mortality rate was 26%. Similar study by 
chastre J Fagon JY et al 31who proved the mortality rates to be 25% is in great 
support of this study. It was seen that the mortality was significantly high in 
patients with multidrug resistant Pseudomonas. Mortality was predominately 
related to underlying diseases like Guillian barre syndrome and in Poisoning 
cases and also duration of hospital stay, patients with hospital stay more than 
15 days showed high mortality. Similar study by Panwar Rakshit et al111 also 
demonstrated  that  mortality  was  significantly  high  in  co  morbid  illness 
colonized with Pseudomonas.  Virulence factor of  Pseudomonas with steroid 
therapy and prolonged stay in hospital might be a reason for high incidence of 
mortality.           
SUMMARY
The analysis of 100 samples collected from Ventilator Associated Pneumonia 
cases admitted in respiratory care unit of Government Rajaji Hospital showed 
that  Ventilator  Associated  Pneumonia  was  more  preponderant  in  males,  the 
common age group being 21- 40 years in both sexes. The clinical condition 
most  often  associated  with  Ventilator  Associated  Pneumonia  was 
poisoning.71.4% of Gram negative and 16.1% of Gram positive organisms and 
12.5%  fungi  were  isolated.  28.6%  of  Gram  negative  organisms  were 
Pseudomonas  aeruginosa  and  12.5%  of  Gram  positive  organisms  were 
Staphylococcus  aureus  and  10.7%  were  Candida  species.  Pseudomonas 
aeruginosa  and  Candida  species  were  commonly  present  in  patients  with 
Guillian barre syndrome and Poisoning, whereas Staphylococcus aureus were 
present in multiple injuries. 
On the analysis of the three different types of  samples collected in this study 
(i.e.)Endotracheal aspirate, Bronchoscopic  Bronchoalveolar lavage and blood 
culture,  the  former  two techniques  (i.e.)  Endotracheal  aspirate  (75.9%) and 
Bronchoalveolar  lavage  (84.7%)  yielded  equal  positivity  in  the  isolation, 
whereas blood culture yielded less positivity (29%). 
The organism isolated in  the three  types of  samples (Endotracheal  aspirate,  
Bronchoscopic bronchoalveolar lavage and blood culture) were same in all the 
cases showing that all  these cases were pulmonary infection,  not associated 
with any additional source of infection.
 
75% of  pseudomonas  aeruginosa  isolated  were  multidrug  resistant,  69% of 
Klebsiella  pneumonia  was  multidrug  resistant  and  100% of  staphylococcus 
aureus  were  methicillin  resistant  staphylococcus  aureus  (MRSA).  The 
resistance of  organism to antibiotics might  have played a major  role in  the 
occurrence of Ventilator Associated Pneumonia in these patients on mechanical 
Ventilation. 
It  was also noted that mortality rate in ventilator associated pneumonia was 
26%.  The  rate  was  significantly  high  in  patients  with  multidrug  resistant 
Pseudomonas  aeruginosa,  predominately  related  to  underlying  diseases  like 
Guillian barre syndrome and poisoning and also in patients with hospital stay 
more than 15 days.
CONCLUSION
A study on microbial etiology of ventilator associated pneumonia Conducted at 
Government Rajaji Hospital, Madurai during the period from May 2008 to 
December 2008, revealed the following findings
  Male predominance in the age group 21- 40 years,  especially 
in the poisoning cases on mechanical ventilation noted.
  Pseudomonas  aeruginosa  among  gram  negative  and 
Staphylococcus  aureus  among  gram  positive  organisms  and 
Candida among fungi were commonly isolated.
 Comparative  study  of  the  three  methods  of  collection  of 
samples  revealed  that  the  samples  collected  by  endotracheal 
aspirate  and  bronchoalveolar  lavage  yielded  organisms 
equally  both  in  specificity  and  Quantitation.  Blood  culture 
showed less positivity. 
 Pseudomonas  aeruginosa,  Klebsiella  pneumonia  and 
Staphylococcus  aureus  were  highly  resistant  for  multiple 
drugs.
 Mortality  rate  was  high  in  patients  with  multidrug  resistant 
Pseudomonas  with  underlying  diseases  like  Guillian  barre 
syndrome  and  Poisoning  and  also  in  patients  with  hospital  stay 
more than 15 days.
OUTCOME OF STUDY
Ventilator  associated  pneumonia  is  considered,  a  serious  infective  condition 
related to high mortality rate, hence it needs a prompt diagnosis and proper 
Antibiotic  treatment.  In  this  study also there  is  high incidence of  ventilator 
Associated Pneumonias and important factors which increase the vulnerability 
to  acquire  Ventilator  associated  pneumonia  were  prolonged  hospital  stay, 
implication  of  organisms  with  multidrug  resistance  and  predisposing 
underlying diseases. The pathogens isolated could have possibly been present 
in  the  hospital  environment.  Hence  strategies  to  bring  down  incidence  of 
Ventilator Associated Pneumonia and thus prevent considerable morbidity and 
mortality.
1. A well monitored hospital infra surveillance system has to be in place
2. Effective implementation of sterilisation and disinfection procedures to 
     be adopted
3. A policy on rational use of antibiotic to be implemented
However, prompt and early diagnosis of pneumonias would be the mainstay in 
bringing down mortality. Endotracheal aspirate samples have been found to be 
very useful in isolation of etiological agents and should be sent to the clinical 
Microbiology lab as early as possible in a patient on mechanical ventilation 
more than 48hours.
ANNEXURE 1
GRAM STAINING:
The gram stain was prepared as follows:
PRIMARY DYE:
Crystal violet                            - 10g
Ammonium oxalate                 - 4.25g
Absolute alcohol                       - 50ml
Distilled water                        -500ml
The  methyl  violet  dye was  dissolved in  50 ml  absolute  alcohol  and mixed 
thoroughly.  Then  ammonium  oxalate  4.25  g  was  dissolved  in  100  ml  of 
distilled  water  and  this  mixture  was  added  to  the  violet  stain  and  finally 
distilled water was added to make 500 ml. The total mixture was filtered before 
use.
Gram’s iodine solution consists of the following
Iodine             - 25g
KI                  - 50G
DW               - 500ml
 Fifty grams of KI was dissolved in 500 ml of water and then 25 grams of 
iodine was added to that. When iodine is dissolved, the solution was made up 
to 500ml with distilled water.
Counter stain used in grams stain was dilute carbol fuschin. It consists of the 
following:
Basic fuschin         - 5g
Phenol                   -25g
Absolute alcohol   -50 ml
The  basic  fuschin  powder  was  added  to  alcohol  at  intervals  until  it  was 
dissolved. Then phenol too was dissolved in distilled water. Both the solution 
was mixed in a separate container.
CATALASE TEST:
Done by both slide & tube methods.
Tube method:
A small amount of the culture was picked up from the nutrient agar plate with a 
clean, sterile glass rod and inserted into a tube of 3% hydrogen peroxide; there 
was no effervescence or bubble formation.
Slide method:
Pure growth of the organism from the agar was transferred to a clean slide with 
a sterile glass rod. Immediately 2 to 3 drops of 3% hydrogen peroxide was 
added to the growth, observed for the release of the bubbles.
ANNEXURE 2
MEDIA PREPARATION
1. Peptone water:
            Peptone               1 g
           
           Sodium chloride   0.5 g
           
           Distilled water      100 ml              PH – 7.4
  
Sterilise by autoclaving at 121d C for 15 minutes.
 
2. Nutrient broth :
           Peptone water     100ml
          
           Beef extract         1 g
          
           Ph                       7.4
   
 Sterilise by autoclaving at 121dC for 15 minutes.
   
3. Nutrient agar :
   To the nutrient broth, add required amount of agar. Steam to dissolve 
agar, filter, and adjust ph to 7.4. Sterilise by autoclaving at 121dC for 15 
min.
4. Blood agar :
    To the 100 ml of nutrient agar, in water bath at 50dC, add 5% (5ml) of 
Sheep blood.
5. Mac conkey agar
                Peptone                         20 g
               
                Sodium chloride            5 g
              
                Sodium taurocholate     5 g
             
                Lactose                          10g
             
                Neutral red                    10 ml
                
                Agar                              15 g
                
               Distilled water               1000 ml
       
  Sterilise by autoclaving at 121dC for 15 minutes.
      
6.  Muller Hinton media:
         Beef infusion                  300 g/l
         
         Casein acid hydrolysate    17.5 g
          
         Starch                               1.5 g
          
         Agar                                 17 g
          
        Distilled water                  1000 ml 
            
Sterilise by autoclaving at 121dC for 15 minutes.
ANNEXURE 3
 PROFORMA FOR VENTILATOR ASSOCIATED PNEUMONIA
CASE HISTORY:
Name:                                                Age:
Sex
Occupation: 
Address:                                           
Duration:
(Pt on ventilator)
Diagnosis:
Risk factors:
1. Chronic  lung  disease
2. Head  trauma
3. Burns
4. Prior antimicrobial therapy
5. Thoracic or abdominal surgery
   CLINICAL PULMONARY   INFECTION SCORE
Temperature  36.5 &< 38,4
 38.5&< 38.9
<    36&  > 39
Point- 0
Point- 1
Point- 2
Blood leukocytes >4000 & < 11000
<4000 & > 11000
>500 band forms
Point- 0
Point- 1
Point- 1
Tracheal secretion Absence of tracheal 
secretion
Presence of non 
purulent secretion
Presence of  purulent 
secretion
Point- 0
Point- 1
Point- 2
Pao2/ Fio2 >240 or ARDS
<240  or ARDS
Point-0
Point- 2
Xray chest No infiltrate
Diffuse infiltrate
Localised infiltrate
Point- 0
Point- 1
 Point- 2
Progression of 
pulmonary infiltrate
No radiographic 
progression
Radiographic 
progression
Point-0
Point-2
Culture& gram stain of 
tracheal secretion
No pathogenic bacteria
Pathogenic  bacteria in 
culture & gram stain
Point-0
Point- 1
 
CPIS SCORE > 6   Diagnosis of VAP
ANNEXURE 4
LABORATORY REPORT
   
 CULTURE   MATERIAL
   
   1. ENDO TRACHEAL ASPIRATE
  
  2. BRONCHO ALVEOLAR LAVAGE
    
  3. BLOOD CULTURE
    
    DAY- 1
GRAM STAIN:
    DAY- 2
CULTURE:
NUTRIENT AGAR PLATE:
MAC CONKEY AGAR PLATE:
BLOOD/ CHOCOLATE AGAR PLATE:
    DAY- 3 
BIO CHEMICAL REACTIONS:
INDOLE-
TSI      -
CITRATE-
UREASE-
 
OTHER SPECIAL TEST:
COAGULASE TEST-
CATALASE TEST-
OXIDASE TEST-
BILE SOLUBILITY-
ANTIBIOTIC SENSITIVITY:
SENSITIVE DRUGS
RESISTANT DRUGS
REPORT:
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